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The beginning of the 20th century marked the dawn of modern medicine with glycan-based therapies at the
forefront. However, glycans quickly became overshadowed as DNA- and protein-focused treatments
became readily accessible. The recent development of new tools and techniques to study and produce struc-
turally defined carbohydrates has spurred renewed interest in the therapeutic applications of glycans. This
review focuses on advances within the past decade that are bringing glycan-based treatments back to the
forefront of medicine and the technologies that are driving these efforts. These include the use of glycans
themselves as therapeutic molecules as well as engineering protein and cell surface glycans to suit clinical
applications. Glycan therapeutics offer a rich and promising frontier for developments in the academic,
biopharmaceutical, and medical fields.Glycans are a universal and essential component to life as we
know it. They can be found as large structural polysaccharides,
secreted mucus components, or protein and lipid conjugates,
ranging in size from a singlemonosaccharide to polysaccharides
thousands of units long (Ju et al., 2011; Hanisch, 2001; Wen-
nekes et al., 2009; Apweiler et al., 1999; Somerville, 2006).
Sugars coat the cells of every organism and are estimated to
be the most abundant class of organic molecules on Earth (Mo-
hanty et al., 2000; Weinbaum et al., 2007). However, while the
structures of the monosaccharides were first elucidated by
Fischer in the mid-1880s (Fischer and Bergmann, 1909), it took
nearly a century before scientists began to appreciate the com-
plex roles that these molecules played in biology (Bertozzi and
Kiessling, 2001; Rademacher et al., 1988; Varki, 1993). This lag
in understanding glycan structure and function is in part due to
the complexity inherent to the regulation and assembly of these
biomolecules. Glycans are not directly encoded by the genome
and thus their biosynthesis and make-up is dictated by meta-
bolism, signal transduction, and cellular status (Dennis et al.,
2009; Parker and Kohler, 2010; Yarema and Bertozzi, 2001).
Additionally, they can be connected by an array of linkage regio-
chemistries and stereochemistries, leading to large structural
diversity that can then be further elaborated by functional group
modifications (Cummings, 2009; Gabius et al., 2004; Muthana
et al., 2012).
It is now well recognized that glycans play an essential role in
a myriad of biological events including cellular adhesion and
migration, organism development, disease progression, and
the modulation of immunological responses (Haltiwanger
and Lowe, 2004; van Kooyk and Rabinovich, 2008; Ohtsubo
and Marth, 2006; Spiro, 2002). Although much effort has been
spent on the study of glycans and how they affect disease, clini-
cians and medicinal chemists rarely consider glycans as biolog-
ical targets or drugs (Ernst andMagnani, 2009). This unfamiliarity
is beginning to change as improved methods for carbohydrate16 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rsynthesis (Boltje et al., 2009; Lepenies et al., 2010; Zhu and
Schmidt, 2009), sequencing (Alley et al., 2013; Zaia, 2008), and
biological analysis (Laughlin and Bertozzi, 2009; Liang et al.,
2008) of glycans become more sophisticated and widely avail-
able. This review focuses on a redefined approach to engineer
glycan components for biomedical purposes that has emerged
from the assimilation of carbohydrate chemistry, chemical
biology, and glycobiology. Built on decades of carbohydrate
research and tool development, scientists are creating improved
or novel glycan products to control human health and disease.
The realm of glycoengineering remains a young and exciting
yet largely unexplored area in the creation of new therapeutics
and medical treatments.
The History of Glycan Structures in Medicine
Much like protein and DNA biomolecules, glycans have had a
very rich history in medicinal use. However, with the discovery
of the genetic code and the ensuing DNA technologies, glycans
and lipids became less appreciated as the other two main mo-
lecular constituents of life. Nevertheless, this brief omission
has not reduced their importance or potential for therapeutic
relevance (Marth, 2008). This is especially apparent with the
rise in obesity and type II diabetes in which the role of lipids
and glycans are essential to understanding and treating this bur-
geoning epidemic (Smyth and Heron, 2006). This section of the
review will focus on the emergence of glycans themselves as
administered therapies in the clinic, which provided some of
the first major breakthroughs in modern medicine (Figure 1).
In 1900, Karl Landsteiner reported on the discovery of three
blood types, A, B, and O, which governed compatibility in blood
donor matching and allowed for the first successful blood trans-
fusion to be performed by 1907 (Landsteiner, 1900). This discov-
ery would garner him the Nobel Prize in Medicine in 1930 but the
structures of the ABO constituents were not revealed until
50 years later. Studies to identify the chemical identities of theights reserved
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Figure 1. Timeline of Glycans in Medicine
The first half of the 20th century was marked with major breakthroughs in glycan-based treatments. However, further progress was dampened by a lack of
structural understanding that was not available until the past 60 years. A large number of discoveries in the 1980s elucidated the molecular and mechanistic
details of glycan-mediated biological events and provided the impetus to expand the use of glycans in therapeutic endeavors.
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both a source for copious active compound was found (ovarian
cysts) and plant lectins that agglutinated blood group specific
cells were discovered (Watkins, 2001). Work by Kabat, Morgan,
and Watkins demonstrated that the main component of the H
antigen was the monosaccharide fucose upon which N-acetyl-
galactosamine (GalNAc) or galactose (Gal) were added to form
the A and B antigens, respectively (Kabat and Leskowitz, 1955;
Morgan and Watkins, 1953; Watkins and Morgan, 1955). The
full structures were then elucidated in the 1960,’s with the clever
use of selective alkylation chemistry coupled with enzymatic and
acid/base hydrolysis to determine the monosaccharide linkages
and components (Watkins, 2001).
The discovery and use of the polysaccharide heparin for treat-
ment of thrombosis in humans has made a huge and lasting
impact on the medical community. Heparin was first discovered
in 1916 (McLean, 1916) and through advances in isolation from
animal sources, it was used clinically by the 1930s (Lever
et al., 2012). By the mid-20th century, most industrial heparin
was isolated from porcine mucosa, which remains the main
source for the 100 tons of heparin used per year. Investigations
into heparin’s mode of action led to the discovery of
antithrombin III, whichwas found tobenecessary for heparin’s in-
hibition of the clotting cascade initiators, thrombin and factor Xa
(Brinkhous et al., 1939; Lindahl et al., 1979). The structure of the
basic disaccharide unit of heparin was not elucidated until much
later and found to consist of sulfated glucosamine and iduronic
acid, identifying heparin as a glycosaminoglycan (GAG; Lindahl
et al., 1980). Interestingly, endogenous human heparin is found
exclusively in a subset of mast cells where it appears to control
the constituentsof its granulesused for immunological protection
(Humphries et al., 1999). These discoveries, along with its clinical
success, have made heparin a billion-dollar industry and rich
source for further investigations discussed in later sections.
In 1917, Dochez and Avery reported that a ‘‘soluble-specific
substance’’ shed from Pneumococcus could react with type-
specific antisera from patients infected with the pathogen (Do-
chez and Avery, 1917). Five years later, Avery teamed up withChemistry & BiolHeidelberger, an early leader in the field of antibodies, to report
that this substance was a type-specific polysaccharide-based
soluble material (Heidelberger and Avery, 1923). Although this
was initially met with much skepticism (Van Epps, 2005), by
1930, Francis and Tillett identified that this capsular polysaccha-
ride could be used as a main component for vaccine develop-
ment against Pneumococcus (Francis and Tillett, 1930;
Heidelberger et al., 1950; MacLeod et al., 1945). Therapeutic
products based on this polysaccharide have historically had a
variety of clinical uses and are used in the vaccine Pneumovax
(PPV23), which contains 23 purified capsular polysaccharides
from Streptococcus pneumonia (Barocchi et al., 2007). While
few subsequent polysaccharides from other pathogens were
able to alone provide adequate antibody responses for vaccina-
tion, these discoveries proved that carbohydrates could make
successful vaccines and gave the impetus to explore their further
use, a main topic in this review.
Aminoglycosides are a class of amine containing small
molecule glycans synthesized by the Streptomyces and Micro-
monospora genus of Gram-positive bacteria. The first amino-
glycoside, streptomycin, was discovered in 1943 and found
expedient clinic use as the first antibiotic for the successful
treatment of tuberculosis (Schatz et al., 1944). Other members
of this widely used class of antibiotics include gentamicin,
kanamycin, and neomycin. Most function as protein synthesis
inhibitors though the exact mechanism of all the aminoglyco-
sides is not fully understood (Wang et al., 2012). Unfortunately,
the rapid onset of bacterial resistance to aminoglycosides has
led to a steady decline in their clinical use, but the increase in
multidrug resistant strains has renewed interest to block
resistance or engineer new target compounds (Becker and
Cooper, 2013).
While the concept behind the imagingmodality, positron emis-
sion tomography (PET), was first developed in the 1950s, it was
the synthesis and use of 2-fluorodeoxy-D-glucose (FDG)
20 years later that brought this technology to the forefront of clin-
ical oncology (Kelloff et al., 2005; Reivich et al., 1979). 18FDG is
taken up more quickly by cells with high metabolic demandogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 17
Figure 2. Structures of Glycan-Based Small Molecule Drugs Currently on the Market or in the Pipeline
All compounds are natural products or based on a carbohydrate scaffold. Their uses range from the prevention of bacterial (neomycin) and viral infection
(oseltamivir, zanamivir) to the treatment of glycan-based diseases (miglitol, diabetes; miglustat, Gaucher), sickle cell crisis (GMI-1070), and as an anticoagulant
(fondaparinux).
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mors and imaging of the brain (Ametamey et al., 2008). It would
take several decades before alternative methods for the direct
imaging of glycans and other biomolecules would appear, which
has been covered extensively and not discussed further in this
review (Laughlin and Bertozzi, 2009; Boons, 2010; Cipolla
et al., 2011; Chang and Bertozzi, 2012).
Advances in Glycobiology Enable Gycoengineering
of Novel Therapeutic Agents
Despite these early successes in bringing carbohydrates to the
clinic, the remainder of the 20th century was fraught with diffi-
culties in the field of carbohydrate research. Synthetic endeavors
failed to produce a facile method to produce large quantities of
glycans for studies while the analytical methods to separate het-
erogeneous natural polysaccharides were still in their infancy.
Several key findings in the latter half of the 20th century pertaining
to specific glycan structure activities led to the development of
new techniques and the founding of glycobiology as its own field
of research (Bertozzi and Kiessling, 2001; Rademacher et al.,
1988). It wasn’t long before scientists began to implement this in-
formation to engineer carbohydrates with distinct properties for
use in the clinic.18 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rEngineered Glycans and Glycan Mimics as Therapeutic
Agents
Glycan Small Molecule Drugs
The majority of small molecule glycan-based drugs thus far have
been carbohydrate binding protein (lectin) or glycosidase inhibi-
tors (Figure 2; Asano, 2003; Brown et al., 2007; Ernst and Mag-
nani, 2009). Themost successful drugs to come from engineered
sugar moieties have been the antiviral compounds zanamivir
(Relenza) (von Itzstein et al., 1993) and oseltamivir (Tamiflu;
Asano, 2003). The life cycle of the influenza virus involves the
binding of viral hemagglutinin (HA) to sialic acid-containing gly-
cans on host cell surfaces. These same glycans then serve as
substrates for viral neuraminidase (NA) to ensure virus release
and maturation (Shriver et al., 2009). Zanamivir and oseltamivir
function by binding with nanomolar affinity to NA and halting viral
budding as well as viral entry into cells (Matrosovich et al., 2004).
Acquired resistance to oseltamivir has provided the impetus to
design new drugs that target the influenza virus. In this regard,
theWithers group has recently designed a difluorinated covalent
NA inhibitor (Kim et al., 2013).
Other successful glycan pharmaceuticals include the type II
diabetes mellitus drugs miglitol (Glyset) and acarbose (Precose,
Glucobay), which inhibit glucosidases and amylases in the gutights reserved
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butyl-deoxynojirimycin) is a drug developed by Actelion and
used primarily to treat the lysosomal storage disease type 1
Gaucher disease. Miglustat is an imino sugar first synthesized
by Butters and Dwek who found that N-alkylated analogs of the
natural product deoxynojirimycin were inhibitors of the glucosyl-
transferase involved in glucosylceramide biosynthesis (Abian
et al., 2011;Platt et al., 1997). Treatmentwithmiglustatwasshown
to alleviate the built up of sphingolipid seen in Gaucher disease.
Many factors thatmanagebacterial adhesiononhost cells are lec-
tinsand thusmuchworkhasbeendirected towardcreatingglycan
based molecules to inhibit this interaction (Ernst and Magnani,
2009; Imberty et al., 2008). The most successful have been tar-
geted to binding the PA-IL andPA-IIL virulence factors inPseudo-
monas. aeruginosa and FimH of Escherichia. coli, both of which
are opportunistic pathogenswith increasing antibiotic resistance.
Glycosaminoglycans (GAGs) are a class of highly charged
linear polysaccharides found secreted and connected to the
cell surface that play a large role in physiology and development
(Bishop et al., 2007; Sasisekharan et al., 2006). The structural
elucidation of the most famous clinical GAG, heparin, in 1982
(Thunberg et al., 1982) enabled the synthesis of the fully active
heparin pentasaccharide 1 year later (Linhardt, 2003). This
advance led to the development of the first synthetically defined
small molecule heparin, fondaparinux (ARIXTRA,) which has
been on the market since 2002 (Petitou and van Boeckel,
2004). Due to its small size and longer half-life, fondaparinux
has enhanced potency and reduced risk of heparin-induced
thrombocytopenia (Maccarana and Lindahl, 1993). The chemo-
enzymatic synthesis of a pentasaccharide heparin has also
recently been reported (Xu et al., 2011). The importance of
generating a defined heparin therapeutic was emphasized in
2008 when an oversulfated chondroitin sulfate contaminant led
to an international health crisis (Liu et al., 2009). A similar
approach has been used to synthesize a 3-O-sulfated heparin
octasaccharide, which binds Herpes simplex virus type 1
(HSV-1) and blocks its entry into the cell (Copeland et al., 2008).
The discovery of selectins in the late 1980s was a major
advance in the field of glycobiology that has inspired several de-
cades of therapeutic development. The selectins control the
attraction of leukocytes to sites of inflammation through the bind-
ing of the sialyl Lewis x (sLex) and sialyl Lewis a (sLea) carbohy-
drate structures (Bevilacqua et al., 1991; Lasky, 1995). Beyond
leukocyte homing to sites of inflammation (Imhof and Aurrand-
Lions, 2004), sLex also plays a significant role in tumor migration
(Schultz et al., 2012) and has recently been shown to be a neces-
sary ligand for human sperm binding to the zona pellucida during
fertilization (Pang et al., 2011). Despite early excitement in
designing small molecule glycan structures such as Cylexin
(CY-1503) to inhibit the selectins, many clinical trials have been
stopped (Kerr et al., 2000). Nevertheless, fucosylated mimics of
the Lewis structures are providing promising leads in current clin-
ical trials for the treatment of asthma (Bimosiamose, TBC-1269;
Kogan et al., 1998) and sickle cell crisis (GMI-1070; Chang
et al., 2010).Recently, Ernst andcoworkers usedannuclearmag-
netic resonance-guided fragment screen to design ligandswith a
sLex scaffold attached to a second site ligand (Egger et al., 2013).
This approach afforded E-selectin inhibitors with low nM affin-
ities, although these antagonists have yet to be tested in vivo.Chemistry & BiolThe dynamic intracellular glycosylation of proteins with N-ace-
tylglucosamine termed O-GlcNAcylation has also gained the
attention of themedicinal community due to its altered regulation
in cancer, diabetes, obesity, and Alzheimer disease (Bond and
Hanover, 2013;Slawsonet al., 2010). TheO-GlcNAcylationmodi-
fication is controlled by two enzymes, glycosyltransferase uridine
diphosphate-N-acetyl-D-glucosamine:polypeptidyl transferase
(OGT) and O-GlcNAcase (OGA), which respectively install and
remove O-GlcNAc from Ser and Thr residues. Although small
molecule regulation of these enzymes is still in its infancy, the lab-
oratoryofDavidVocadlohasdevelopedaselective, lownM inhib-
itor of OGA, thiamet-G (Yuzwa et al., 2008). Treatment of rodents
with thiamet-G was found to increase O-GlcNAcylation levels in
the brain, which decreased tau aggregation and neuronal cell
loss in amousemodel ofAlzheimer’sdisease (Yuzwaet al., 2012).
New methods employing carbohydrate scaffolds are being
utilized to screen the glycan chemical space for more potent in-
hibitors of lectins involved in disease states (Diot et al., 2011; Fer-
reira et al., 2010; Weı¨wer et al., 2009). In addition to the com-
pounds reported above, many natural products are
glycosylated, which influences their efficacy and specificity.
These products constitute a rich field that is beyond the scope
of this review (La Ferla et al., 2011; Ostash et al., 2010).
Polyvalent Glycan Structures and Inhibitors
A major constraint with small molecule, monovalent glycan
structures as targets is that their lectin binding interactions are
often too weak to be employed as suitable drug candidates. In
this regard, the carbohydrate and polymer chemistry commu-
nities have successfully developed multivalent glycoconjugates
which take advantage of the known ‘‘cluster glycoside effect’’
to enhance lectin avidity (Becer, 2012; Deniaud et al., 2011;
Lundquist and Toone, 2002). These approaches have resulted
in three major types of glycosylated macromolecular structures:
glyconanoparticles, glycopolymers, and glycodendrimers
(Becer, 2012; Chabre and Roy, 2008; Marradi et al., 2013). While
many of thesematerials are still in their infancy in terms of biolog-
ical application, they represent the next wave of glycan-based
technologies to fill the therapeutic pipeline.
The most clinically promising scaffold employed thus far has
arguably been the glycodendrimer (Chabre and Roy, 2008;
Mintzer et al., 2012). Dendrimers are single molecular weight,
globular structures which contain a central core, branching
layers, and numerous functionalized end groups (Newkome
and Shreiner, 2008, 2010). Though glycodendrimers have
been synthesized for decades (Yuan, 1978), one of the
first therapeutically relevant successes was the design of
STARFISH; an oligovalent dendron-like compound bearing
Gb3 trisaccharide analogs (P
k) attached to a glucose pentava-
lent core (Figure 3A). The Gb3 glycan is a known ligand for the
multimeric Shiga-like toxins I and II, found in pathogenic
E. coli. The multivalent display of Pk in STARFISH demonstrated
an in vitro inhibitory activity against Shiga-like toxin that was
1–10-million-fold higher than any other known univalent ligands
(Kitov et al., 2000). Similar approaches have been used to also
bind and neutralize cholera toxin and heat-labile enterotoxin.
Dendrimers bearing the sialic acid containing pentasaccharide,
GM1, were generated that could increase in vitro binding to the
toxins and inhibit their cellular toxicity (Pukin et al., 2007; Sisu
et al., 2009).ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 19
Figure 3. Polyvalent Glycan Structures Designed for Increased Avidity to Target Lectins
(A) STARFISH, a Shiga-like toxin inhibitor.
(B) Sulfated lactose PEO star dendrimer to inhibit selectins.
(C) High mannose dendrimers, which inhibit DC-SIGN mediated HIV infection.
(D) PolyBAIT, which inhibits Shiga-like toxin and increases its clearance.
(legend continued on next page)
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or imagemammalian carbohydrate binding proteins. Chaikof and
coworkers demonstrated that a high valency poly(ethylene oxide)
(PEO) star dendrimer bearing highly sulfated lactose ligands
couldbindwith high affinity to the selectins and reduce inflamma-
tion when administered in a mouse model (Figure 3B; Rele et al.,
2005). The Davis research group has also created multimeric se-
lectin ligands by conjugating sLex to glyconanoparticles consist-
ing of cross-linked amine-functionalized iron oxide (Figure 3H).
Because iron oxide is an approvedMRI contrast agent, the ability
of the particles to target selectins enabled the successful in vivo
imaging of cerebral inflammation in animal models of multiple
sclerosis and stroke (van Kasteren et al., 2009).
Due to its role in the dissemination of many pathogens, den-
dritic cell-specific intercellular adhesion molecule-grabbing
nonintegrin (DC-SIGN) has been a popular target for many den-
drimer constructs. DC-SIGN is a C-type lectin present on both
macrophages and dendritic cells that is exploited by pathogens
such as HIV, Ebola, and Mycobacterium tuberculosis to spread
and evade the immune system (van Kooyk and Geijtenbeek,
2003). In 2008, Wong and coworkers developed an oligoman-
nose dendron that inhibited binding of the mannosylated HIV
envelope protein, gp120, to anti-HIV antibodies and a recombi-
nant dimeric DC-SIGN with IC50 values in the nanomolar range
(Wang et al., 2008b). Since then, other groups have shown
they could inhibit HIV trans-infection by blocking HIV with nano-
particles bearing mannose dendrimers (Martı´nez-Avila et al.,
2009). Recent evidence has demonstrated that a high mannose
dendrimer mimic can successfully inhibit DC-SIGN-mediated
HIV infection in cellular and human uterine cervix explant models
(Figure 3C; Berzi et al., 2012; Sattin et al., 2010).
The Davis research group has developed methodology in
which glycodendrimers are attached to multiple sites on a pro-
tein to produce a highly valent ‘‘glycodendriprotein’’(Rendle
et al., 2004). This technology was employed in the conjugation
of mannose dendrimers to Qb self-assembling protein icosahe-
drons. The resulting ‘‘glycodendronanoparticles’’ are the most
highly valent glycodendrimeric constructs yet seen with diame-
ters of up to 32nm corresponding to 1,620 glycan units
(Figure 3G). Using these supervalent constructs, they were
able to inhibit the Ebola infection of dendritic cells by blocking
viral binding to DC-SIGN (Ribeiro-Viana et al., 2012). In an
attempt to increase delivery of vaccines to dendritic cells
(DCs), the van Kooyk lab has generated poly(amido amine)
(PAMAM) dendrimers conjugated to the tetrasaccahride Leb, a
known DC-SIGN ligand (Garcı´a-Vallejo et al., 2013). When these
dendrimers were attached to the OVA peptide as an antigen,
they produced stronger DC activation and subsequent T cell
stimulation than previous Lewis glycan conjugates to the OVA
protein alone (Singh et al., 2009).
Sialic acid binding immunoglobulin-like lectins (Siglecs) are a
class of cell surface receptors that are differentially expressed
in hematopoietic cells and have been regarded as promising tar-
gets for drug delivery and cancer therapies (Jandus et al., 2011;(E) CS-E glycopolymer mimic for controlling neuronal healing.
(F) SET-LRP glycopolymers with controlled assembly for DC-SIGN binding.
(G) Qb glycodendronan particle that inhibits DC-SIGN-dependent Ebola infection
(H) Iron oxide sLex nanoparticels for selectin imaging.
(I) Lipid nanoparticles for delivery to Sialoadhesin cells.
Chemistry & BiolO’Reilly and Paulson, 2009). The Paulson group has developed
diversified sialoside libraries to identify new carbohydrate-based
ligands for the Siglecs (Blixt et al., 2008; Rillahan et al., 2012).
They have utilized these specific ligands for therapies to direct
toxic virus-like particles and lipid nanoparticle carriers to partic-
ular leukocytes and lymphomas based on their Siglec expres-
sion (Figure 3I; Rhee et al., 2012; Chen et al., 2010, 2012b;
Nycholat et al., 2012). These approaches provide new targets
and support ongoing efforts in targeted gene delivery and tar-
geted anticancer therapies.
The Kiessling research group has made important contribu-
tions to the glycopolymer field showing that the architecture of
multivalent ligands is a key aspect governing activity. In effect,
a designed scaffold can be required in some instances to
enhance avidity and specificity (Gestwicki et al., 2002; Kiessling
and Grim, 2013). Working on this notion, Bundle and coworkers
improved their previous STARFISH inhibitor by creating glyco-
polymers composed of a monomer containing the Pk glycan
linked to cyclic pyruvate ketal (CP) called (S)-PolyBAIT
(Figure 3D; Kitov et al., 2008). CP is a known binder of serum am-
yloid P component (SAP), an endogenous protein that is able to
target bound ligands for clearance and plays an important role in
Shiga-like toxin clearance. An intravenous injection of this poly-
mer protected 100% of mice that were subcutaneously injected
with a lethal dose of Shiga-like toxin I. Interestingly, mice that
were given a copolymer in which Pk and CP were randomly
distributed developed severe signs of Shigatoxemia. These re-
sults highlight the importance of ligand placement on a poly-
meric scaffold in recruiting the necessary protein components
for toxin clearance and drug efficacy.
Further demonstrating the importance of ligand placement in a
glycan construct, the Davis group was able to generate a syn-
thetically defined mimic of P-selectin-glycoprotein-ligand-1
(PSGL-1). Using a mixture of the copper-catalyzed azide alkyne
cycloaddition (CuAAC) and their glycomethanethiosulphonates
(glyco-MTS) ligation technology (Davis et al., 1998), they were
able to site-specifically introduce sLex and a sulfated tyrosine
into the bacterial enzyme SSbG. Because these two constituents
are required for specific binding to P-selectin, the galactosidase
(lacZ-type) activity of this glycoengineered SSbG could be used
to stain for P-selectin in chronically inflamed rat cortex (van Kas-
teren et al., 2007).
Whereas homogeneous natural GAGs are nearly impossible to
obtain from natural sources, the Hsieh-Wilson group has pio-
neered the use of ROMP to synthesize GAG glycopolymer
mimics. Previous studies have suggested that the sulfation pat-
terns of chondroitin sulfate (CS) were important for controlling
healing in the nervous system but were limited by the ability to
precisely control chondroitin sulfation patterns (Busch and Sil-
ver, 2007; Lin et al., 2011). Hsieh-Wilson and coworkers showed
that synthesized ROMP-CS mimics were able to inhibit neurite
outgrowth (Rawat et al., 2008), and in follow-up studies, they pin-
pointed this activity to sulfation of the 4- and 6-position of the
galactosamine within CS (Figure 3E; Brown et al., 2012). Using.
ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 21
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specific to the CS-E epitope that could promote axon regenera-
tion in a mouse model of glial scarring in the optic nerve.
The glycopolymer field has recently been propelled by the use
of newly developed controlled radical polymerization techniques
that allow for the assembly of highly defined polymer structures
(Va´zquez-Dorbatt et al., 2012). While many of these materials
have yet to be tested biologically, Haddleton and coworkers
recently reported a method using single-electron transfer living
radical polymerization (SET-LRP) to create a linear copolymer
where for the first time, the position of the sugars could be
controlled (Figure 3F; Zhang et al., 2013). They constructed
multi-block glycopolymers with acrylate monomers consisting
of mannose, glucose, and fucose residues and demonstrated
that only certain clustered mannose monomer structures could
bind to DC-SIGN.
Carbohydrate-Based Vaccines
Carbohydrate-based vaccines have been at the forefront of ef-
forts to bring carbohydrate chemistry into clinically relevant plat-
forms (Boltje et al., 2009; Seeberger and Werz, 2007; Tarp and
Clausen, 2008). Many currently utilized vaccines are comprised
of glycans including vaccinations against Neisseria meningitides
(Menactra), Streptococcus pneumonia (Prevnar), Haemophilus
influenzae type b (Hib; Hiberix, Comvax), and Salmonella typhi
(TYPHIM Vi; Morelli et al., 2011; Seeberger and Werz, 2007).
However, these constructs are derived from natural sources
and utilize nonspecific conjugation methods to carrier proteins.
Herein, we will focus on recent developments in using synthetic
glycoengineered vaccines to create more defined therapeutics.
Advances in the fields of protein conjugation have also
expanded the techniques available to generate carbohydrate
vaccines selectively attached to protein carriers (Gamblin
et al., 2009; Grayson et al., 2011). For those interested, several
reviews are available that cover more in-depth progress of car-
bohydrate-based vaccines against bacteria (Pozsgay, 2008),
HIV (Wang, 2006), and cancer (Cipolla et al., 2008; Ouerfelli
et al., 2005).
Themost successful case to utilize a synthetically defined vac-
cine has been the production of the Cuban Hib vaccine; the first
clinically approved, fully synthetic carbohydrate vaccine based
on the structure of the capsular polysaccharide antigen from
Hib (Figure 4B; Verez-Bencomo et al., 2004). The pentasacchar-
ide conjugated to tetanus toxin (TT) is produced under GMP con-
ditions in scales large enough to be incorporated into Cuba’s
current routine vaccination system. A similar approach was
taken by the Seeberger research group to generate an anti-
malarial vaccine by automated synthesis of the glycosylphos-
phatidylinositol (GPI) from the causative agent of malaria,
Plasmodium falciparum (Figure 4A; Hewitt et al., 2002; Schofield
et al., 2002). Recipient mice were protected against many of the
damaging symptoms normally found during parasite infection
including malarial acidosis, pulmonary edema, cerebral syn-
drome, and death. The same group has also successfully
made a vaccine against the Bacillus. anthracis spore tetrasac-
charide, which was used to raise antibodies against anthrax for
detection and imaging purposes (Tamborrini et al., 2006).
Mulard and coworkers have reported on a synthetic pentade-
casaccharide consisting of three repeating units of the O-spe-
cific polysaccharide (O-SP) domain of Shigella flexneri 2a22 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All r(SF2a) LPS (Figure 4C). This glycan coupled to tetanus toxoid
(TT) elicited a better serum anti-LPS 2a antibody response in
mice than shorter synthetic O-SP sequences (Be´lot et al.,
2004; Phalipon et al., 2006). The immunized mice successfully
produced glycoconjugate-induced anti-LPS antibodies which
afforded them protection against SF2a infection. Preclinical
data suggest these results are also applicable to human treat-
ments (Phalipon et al., 2009). While these previous endeavors
were based on archetypal conjugation techniques with monova-
lent epitopes, newer methods are employing multivalent epitope
structures. A polymer bearing the b-mannan trisaccharide
epitope from the Candida albicans cell wall conjugated to
chicken serum albumin was shown to havemore robust IgG pro-
duction in mice than the trisaccharide-TT conjugate vaccine
alone (Lipinski et al., 2011). In a follow-up study, Bundle and co-
workers were able to use these antibodies to identify a minimal
disaccharide epitope vaccine that could protect rabbits from
fungal burden when challenged with live C. albicans
(Figure 4D; Bundle et al., 2012). The Pier and Nifantiev labs
have also reported a series of synthetic oligoglucosamine vac-
cines that recognize b-(1/6)-poly-N-acetyl-d-glucosamine
(PNAG), a common constituent in the capsular polysaccharide
of many pathogenic bacteria. Antibodies from rabbits immu-
nized with this construct were able to protect mice from
S. aureus and E. coli infections (Gening et al., 2010).
One of the major discoveries to entice the glycobiology field in
the past decade was the isolation of broadly neutralizing anti-
bodies for HIV that bind the high mannose, Man9 glycan of the
HIV envelope protein, gp120 (McCoy and Weiss, 2013; Pejchal
et al., 2011; Walker et al., 2009). The most highly studied variant
is the 2G12 clone which neutralizes by slowing the entry of the
virus into cells and can inhibit replication after passive transfer
into patients (Platt et al., 2012). Other isolated clones such as
PG9 can bind to the glycans from both gp120 and gp140 enve-
lope proteins (Julien et al., 2013). Early attempts to elicit an im-
mune response against the high mannose epitope of gp120 in
a BSA conjugate were performed in rabbits, but the resulting an-
tibodies were unable to bind the native gp120 N-glycans or
neutralize the virus (Astronomo et al., 2008; Joyce et al., 2008).
These results spurred the Davis group to create a vaccine that
used synthetic analogs in place of mannose to create a more
immunogenic, non-self epitope (Figure 4E). Conjugation of this
oligomannose mimic onto the virus-like particle Qb bound with
high affinity to 2G12 and elicited a greater antibody response
than vaccines constructed with only mannose (Doores et al.,
2010). Immunization in rabbits produced antibodies that were
able tobindwell toMan8andMan9 conjugated to cowpeamosaic
virus. Unfortunately, the antibodies did not bind native gp120 or
reduce virus infection implying that the protein carrier is also
crucial to eliciting a successful neutralizing antibody. The Dani-
shefsky group has recently reported on the synthesis of a glyco-
peptide containing the epitope for the PG9 antibody (Aussedat
et al., 2013). The glycopeptide contained the two closely spaced
N-glycans atAsn160 andAsn156 of gp120andcouldbindwith high
affinity to the PG9 antibody, whereas the glycans alone were not
good ligands. Experiments are currently underway to evaluate
their immunogenicity and HIV protection in animal models.
Alterations in the glycosylation of transformed cancer cells
have been observed for decades (Fukuda, 1996; Kloppel et al.,ights reserved
Figure 4. Synthetic Carbohydrate-Based Vaccines
Representative vaccines against microbial pathogen- (A–D), HIV- (E), and cancer-associated (F) glycan epitopes.
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especially pertains to an increase in branched and highly sialy-
lated structures that is often accompanied by an increase in
mucinous proteins such as MUC1 and MUC16 (Hollingsworth
and Swanson, 2004; Kufe, 2009). Unique recurring glycan epi-
topes are referred to as TACAs (tumor-associated carbohydrate
antigens) and have been a predominant target for cancer vacci-
nations (Figure 4F; Pashov et al., 2011). Samuel Danishefsky was
an early pioneer in the use of synthetically defined carbohydrate
vaccines, creating the first synthetic Globo H vaccine for clinical
use (Gilewski et al., 2001; Slovin et al., 1999). His research group
has followed these advances with a vaccine that contains five
prostate and breast cancer-associated carbohydrate antigens,
Globo-H, GM2, STn, TF, and Tn conjugated to the carrier protein
KLH (Figure 4F; Zhu et al., 2009). After initial studies demon-
strating a successful IgG/IgM response in mice, this construct
is currently in clinical trials. Wong and coworkers have also re-
ported on an optimized vaccine against the hexasaccharide
Globo-H. This approach improved upon previous reports by
testing different carrier proteins and adjuvants to improve the
immunogenicity and safety profile (Huang et al., 2013). Globo-
H conjugated to diphtheria toxoid and coadministrated with an
a-galactosylceramide analog adjuvant induced a robust IgG
response against Globo-H including other related structures
specifically found on breast cancer and cancer stem cells. The
Boons research group has reported a three-component vaccine
composed of a TLR2 agonist, a promiscuous peptide T-helper
epitope, and a tumor-associated glycopeptide. The all-in-one
construct was able to elicit high titers of IgG antibodies in mice
that could recognize tumor-associated carbohydrates on cancer
cells (Ingale et al., 2007).
MUC1 was adopted early on as a cancer vaccine target due
to its expression in a wide variety of cancers (Cheever et al.,
2009). However, most of these initial approaches relied on tradi-
tional vaccination means with unglycosylated epitopes (Gilew-
ski et al., 2000). The Boons group applied their three compo-
nent approach to create a MUC1 vaccine consisting of a
GalNAc-glycosylated MUC1 peptide, the T-helper epitope and
the Pam3CysSK4 TLR agonist (Lakshminarayanan et al.,
2012). This was the first example of a MUC vaccine that could
elicit both humoral and cellular immunity leading to high titer
production of IgG against the epitope in mice. The Payne
research group has found comparable success in a similar three
component vaccine approach that can assemble into nanopar-
ticles for adjuvant purposes (Wilkinson et al., 2012). Embracing
a multivalent synthetic approach, Dumy and coworkers have
created self-adjuvanting glyco-lipopeptides bearing their
regioselectively addressable functionalized templates (RAFT)
construct (Renaudet and Dumy, 2003). These include a RAFT
made of four a-GalNAc molecules (Tn antigen), a CD8+ T cell
epitope and a universal CD4+ T-helper epitope attached to
the Pam adjuvant (Bettahi et al., 2009). This construct produced
robust IgG/IgM in mice that recognized tumor cell lines and eli-
cited a reduction of tumor size in mice inoculated with synge-
neic murine MO5 carcinoma cells. Another self-adjuvating
approach involves the use of self-assembling fibrils from the
Q11 peptide domain, which when attached to glycosylated
MUC1 peptides, can induce an adjuvant-free response (Huang
et al., 2012b).24 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rProtein Glycoengineering to Enhance Efficacy
and Therapeutic Value
Most therapeutic proteins are produced as a mixture of glyco-
forms each with its own biological efficacy and properties that
must be fine-tuned for the therapeutic application (Arnold
et al., 2007; Hossler et al., 2009; Sethuraman and Stadheim,
2006). For example, the physical properties of glycosylation
can protect proteins from proteolysis or increase stability and
solubility (Sinclair and Elliott, 2005; Sola´ and Griebenow, 2009).
Additionally, each protein glycoform can have a distinct biolog-
ical response with differences in pharmacodynamics and
effector functions (Ferrara et al., 2011; Jefferis, 2012; Raju,
2008). Yet, isolating homogeneously glycosylated products
and defining their individual in vitro and in vivo functions remains
a daunting task. Even in the simplified case of human IgG anti-
bodies, which have one N-glycosylation site on each of two
heavy chains, up to 500 glycoforms may exist (Jefferis, 2009).
Using current methodology, protein therapeutics must be
constantly monitored and even blockbuster drugs show
changes in glycosylation status over time (Rathore and Winkle,
2009; Schiestl et al., 2011). Two main tactics have emerged to
produce homogeneously glycosylated products and address
these complications. One embraces a chemically defined
approach using synthetic methodology to generate glycosidic
linkages on synthetic or recombinant proteins. Another pursuit
uses engineered enzymatic pathways in vitro or in the expression
host itself to afford pure protein glycoforms (Bennett and Wong,
2007; Rich and Withers, 2009; Wang and Lomino, 2012; Yuan
et al., 2010).
In the late 1970s and early 1980s, it became apparent that the
conserved N-glycan on human IgG was important for not only its
secretion, but also for determining the effector functions of the
antibody through antibody-dependent cellular cytotoxicity
(ADCC) and complement activation (Figure 5; Hickman and
Kornfeld, 1978; Nose and Wigzell, 1983; Tao and Morrison,
1989). It was further shown that this conserved N-glycan at
Asn297 of the Fcmoiety was essential for binding to Fc receptors
(Nimmerjahn and Ravetch, 2005), mannose-binding lectin (Mal-
hotra et al., 1995), and the collectin-related molecule C1q
(Raju, 2008). These discoveries led to the creation of engineered
Chinese hamster ovary (CHO) and human embryonic kidney
(HEK) expression hosts that produced specific glycosylation
structures to direct effector functions toward a particular thera-
peutic application (Crispin et al., 2009; North et al., 2010). This
work began with a CHO line that was engineered to express
b-1,4-N-acetylglucosaminyltransferase III (GnTIII), which adds
a bisecting GlcNAc onto the N-glycan core (Davies et al., 2001;
Uman˜a et al., 1999). Antibodies produced from these cells
showed a substantial increase in ADCC and provided the first
report of a cell line glycoengineered to produce antibodies with
enhanced efficacy for killing cancer cells. It was later found
that the bisecting GlcNAc also blocked core fucosylation and
that the defucosylated Fc was the predominant feature for
increased ADCC. This has led to continued efforts to produce
nonfucosylated antibodies with enhanced Fc receptor binding
(Satoh et al., 2006; Shields et al., 2002; Shinkawa et al., 2003;
Zhou et al., 2008). Glycart Technology, now owned by Roche,
has focused on the production of nonfucosylated antibodies
for enhanced biotherapeutics. Seattle Genetics has alsoights reserved
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Figure 5. Effect of Glycan Structure on IgG
Antibody Effector and Immune Function
Without glycosylation, IgG does not bind Fc re-
ceptors or activate complement, whereas the
addition of different sialic acids can elicit anti-
inflammatory or immunogenic effects.
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fucosylation in vitro and in vivo for production of antibodies
with increased ADCC (Okeley et al., 2013).
In addition to proinflammatory properties, the glycosylation
status of IgG has also been to shown to exhibit anti-inflammatory
effects. Intravenous gamma globulin (IVIg) therapy in which a
heterogeneous population of IgG is injected in the patient has
been implemented for decades to treat inflammatory diseases
(Dwyer, 1992). The Ravetch research group was the first to
demonstrate that this property was due to the sialylation of the
Fc N-glycans. The antennary sialic acid reduced binding affinity
to the activating Fcg receptor-III and increased expression of the
inhibitory Fcg receptor-IIB (FcgRIIB) (Kaneko et al., 2006). They
further demonstrated that a2,6-linked sialic acid conferred this
property which allowed the construction of an antibody contain-
ing increased a2,6-sialic acid for enhanced anti-inflammatory
properties (Anthony et al., 2008). The galactosylation of
N-glycans on IgG1 has also been shown to promote cooperative
signaling of FcgRIIB with dectin-1, resulting in an inhibitory
pathway that blocks the complement cascade and proinflamma-
tory effector functions (Karsten et al., 2012). For those interested
in further reading, the potential for controlling IgG-based thera-
peutics through glycoengineering has recently been reviewed
(Jefferis, 2009).
Beyond antibodies, the extent and composition of glycans can
also affect the efficacy of many other therapeutic proteins.
Recombinant EPO (Epogen) has been widely used for the treat-
ment of anemia, but its expression in mammalian hosts must be
closely monitored as the extent of sialylation on its N-glycans
can heavily affect its pharmacokinetics (Fukuda et al., 1989). In
fact, glycosylation affects the in vivo stability so much that
removal of EPO’s glycans decreases its plasma half-life in
rodents from 5-6 hr to less than 2 min (Erbayraktar et al.,
2003). Using this observation for inspiration, Amgen was ableChemistry & Biology 21, January 16, 201to design a hyperglycosylated form of
EPO, darbepoetin alfa (Aranesp), which
possesses two additional N-glycosylation
sites and a 3-fold prolonged half-life in hu-
mans (Elliott et al., 2003). Darbepoetin alfa
is currently the top choice for EPO treat-
ment as the prolonged half-life increases
potency and reduces the number of
necessary injections. The sialic acid con-
tent and extent of N-glycan branching
on follicle-stimulating hormone (FSH)
also determine the protein’s in vitro activ-
ity as well as its in vivo permanence in cir-
culation (Creus et al., 2001). Introducing
two additional N-glycosylation sites into
FSH increased its size and charge to
reduce renal clearance and enhancebioactivity (Perlman et al., 2003). This same approach was
applied to bispecific single-chain diabodies, where adding extra
N-glycosylation sites also improved pharmacokinetic profiles
(Stork et al., 2008).
A new approach aiming to harness the beneficial effects of sia-
lylation has been the incorporation of polysialic acid (PSA) onto
therapeutic proteins produced in engineered HEK cells (Chen
et al., 2012a). A polysialylated anti-HER2 single-chain variable
fragment (scFv) showed an almost 30-fold increase in blood
half-life but, unfortunately, PSA attachment also decreased re-
ceptor-mediated endocytosis. A sialylation approach has also
been utilized to engineer insulin with a terminal 2,6-SialylLacNAc
dendron. This glycodendrimer construct displayed an increased
half-life and in vivo potency in mice while adding a LacNAc-only
dendrimer did not have this effect (Sato et al., 2004). Sialylated
glycans have also shown to prolong the serum half-life of quan-
tum dots in addition to providing excellent water solubility and
long-term stability (Ohyanagi et al., 2011), whereas quantum
dots with nonsialylated glycans can lead to hepatotoxicity (Kik-
keri et al., 2009).
The previous methods discussed include the production of re-
combinant proteins from mammalian cell hosts. However, these
systems are still very susceptible to glycosylation changes
through alterations in growth environment and are very costly
(Datar et al., 1993; Hossler et al., 2009). Thus, a considerable
amount of effort has been spent on engineering simpler expres-
sion hosts to produce human-like, single glycoform proteins. The
mammalian cellular machinery employs two predominant path-
ways to glycosylate proteins—N-glycosylation and O-glycosyla-
tion. N-glycosylation of eukaryotic proteins begins with a
common oligosaccharide precursor, Glc3Man9GlcNAc2, that is
transferred to the Asn residue of nascent polypeptides in the
endoplasmic reticulum. This is followed by a set of glycosidases
and glycosyltransferases that construct tailored N-glycan4 ª2014 Elsevier Ltd All rights reserved 25
Figure 6. Synthetic and Enzymatic Methods for the Production of Homogeneous Glycoproteins
A glycoprotein with an initial monosaccharide can be generated by total synthesis, enzymatic removal of a heterogeneously glycosylated precursor, or
attachment by a chemoselective reaction. This intermediate can then be further elaborated by enzymatic methods. Additionally, the full-length, fully glycosylated
protein can be synthesized de novo or the complete glycan installed by a chemoselective reaction. X and Y represent functional groups that undergo chemo-
selective reactions.
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lian mucin-type O-glycosylation, identified by a core GalNAc
linkage to Ser/Thr, is more complex in its regulation and is not
present in many lower eukaryotes (Hang and Bertozzi, 2005; Ha-
nisch, 2001).
Gerngross and colleagues at GlycoFi engineered a Pichia
pastoris yeast host that could produce a terminally sialylated
EPO that had full potency in mice. In comparison, the unengi-
neered host produced mostly high mannose N-glycans, which
had minimal in vivo activity (Hamilton et al., 2006). This technol-
ogy was also used to produce sialylated or nonsialylated human-
like N-linked glycoforms of recombinant human lactoferrin. Only
the sialylated structure was able to retain its ability to protect
immune cells from methotrexate-induced death (Choi et al.,
2008). GlycoFi has also used these glycoengineered yeast to
produce single antibody glycoforms which piqued the interest
of Merck to recently acquire the company (Hamilton et al.,
2006; Li et al., 2006).
Callewaert and colleagues have provided an alternative
method to produce glycoengineered yeast using patented
P. pastoris strains and vectors which allow an individual com-
pany or researcher to produce their own glycoengineered yeast
line. This technology was shown to produce relatively homoge-
neous glycoforms of murine IL-10, GM-CSF and IL-22 with a
glycan structure matched to the particular Pichia strain used in26 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rits production (Jacobs et al., 2009). Efforts have also begun to
introduce the mucin-type O-glycosylation machinery into yeast
expression hosts. These glycoengineered yeast were capable
of generating a fully active O-glycosylated human podoplanin
(Amano et al., 2008). Furthermore, plants have now been engi-
neered that can produce fully N- and O-glycosylated EPO con-
taining sialylated biantennary structures (Castilho et al., 2012).
The DeLisa research group has recently reported on an E. coli
host containing the yeast N-acetylglucosaminyl- and mannosyl-
transferases and the bacterial oligosaccharyltransferase from
Campylobacter jejuni. The engineered E. coli could successfully
generate N-glycosylated proteins, such as IgG-Fc and hGH,
bearing the eukaryotic pentasaccharide core (Valderrama-
Rincon et al., 2012).
Instead of engineering the expression host to produce
homogeneous glycans, another approach is to enzymatically
alter the glycans postexpression (Figure 6). A classic example
of this enzymatic tailoring approach is the 1997 paper by Witte
and Wong in which a single glycoform of ribonuclease B was
generated through treatment with glycosidases and glcosyl-
transferases (Witte et al., 1997). This type of engineering is
currently utilized for treatment of the lysosomal storage
disorder, Gaucher disease. To alleviate this enzymatic
deficiency disorder, a glucocerebrosidase enzyme (imiglucer-
ase, Cerezyme) is used that is in vitro deglycosylated, usingights reserved
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dase, to expose terminal mannose residues, which improves
its targeting and internalization (Pastores, 2010). The Lai-Xi
Wang group has had great success in using glycosynthases,
which are glycosidases with engineered glycosyltransferase
activity (Lairson et al., 2008). Implementing activated donors as
substrates, whole glycans can be transferred to create homoge-
neously glycosylated proteins (Huang et al., 2009). Complicated
by low yields and the discrete substrate specificities of the endo-
b-N-acetylglucosaminidases, Endo-A and Endo-M (Fujita and
Yamamoto, 2006; Wang et al., 1997), Wang and coworkers
have optimized a method using an Endo-S mutant to create fully
sialylated antibodies with increased anti-inflammatory activities,
nonfucosylated antibody glycoforms for enhanced FcgIIIa re-
ceptor-binding, and azide-tagged glycosylated antibodies for
further modification of the natural N-glycan structure (Huang
et al., 2012a). They have also utilized this methodology to
remodel the N-glycans produced from a glycoengineered
E. coli expression host (Schwarz et al., 2010). The Tolbert
research group has successfully combined enzymatic glycan re-
modeling with native chemical ligation (NCL) to introduce an
RGD integrin binding motif into a homogeneously glycosylated
Fc construct for targeting cancer cells expressing the avb3 integ-
rin (Xiao et al., 2009).
Approaches utilizing genetic and enzymatic engineering have
arguably provided material that is closest to clinical implementa-
tion and therefore has been a heavy focus in this section. While
synthetic chemistry has successfully provided homogeneously
glycosylated peptides and proteins for investigating glycan func-
tion (Figure 6; Buskas et al., 2006; Pratt and Bertozzi, 2005), the
synthetic methodology remains a technically challenging hurdle
toward producing commercially relevant quantities. Neverthe-
less, we would like to present a few key highlights in the field,
although we also direct the reader to more thorough reviews
(Gamblin et al., 2009; Yuan et al., 2010).
The Kajihara research group has synthesized a fully synthetic
EPOderived frompiecing together solid phase peptide synthesis
fragments by NCL and glycosylation at two native sites by
cysteine alkylation. The synthetic EPO showed cellular activity
comparable to that of the recombinant, naturally glycosylated
protein (Hirano et al., 2009). They have also recently reported
on a synthetic IFN-b construct glycosylated at the natural
Asn80 with a complex sialylated or asialo N-glycan (Sakamoto
et al., 2012). Surprisingly, the IFN-b with a sialylated N-glycan
was a more potent antitumor agent compared to asialo or com-
mercial IFN-b in a mouse tumor model, perhaps leading to the
production of a better therapeutic. The Danishefsky lab has
made progress toward the total synthesis of FSH by also
combining solid phase peptide synthesis and NCL (Nagorny
et al., 2009, 2012). However, the biological efficacy of the fully
glycosylated product has yet to be tested. This group’s recent
advances in NCL combined with metal-free dethiylation to pro-
duce fully functional human proteins will hopefully be used to
expedite the future chemical synthesis of fully glycosylated pro-
teins (Li et al., 2012).
To bridge the high protein production of recombinant systems
with the structural homogeneity of chemical glycan synthesis,
many groups have employed unnatural linkages to introduce
synthetic carbohydrates onto peptide or protein backbonesChemistry & Biol(van Kasteren et al., 2007; Lee et al., 2009; Watt et al., 2003).
Most of these approaches rely on bioorthogonal and chemose-
lective reactions that undergo specific conjugations without
affecting native biological functional groups (Dirksen and Daw-
son, 2008; Sletten and Bertozzi, 2009). Only a few examples
exist that include site-specific chemical glycosylation of full-
length recombinant proteins. The Davis group has focused on
site-specific conjugation with synthetic glycans through disulfide
formation or thiyl radical addition to alkene-containing nonnat-
ural amino acids (Chalker et al., 2011). The Bertozzi and Wong
groups have utilized oxime formation to introduce chemoenzy-
matically derived aminooxy glycans onto specific protein sites
(Hudak et al., 2011; Liu et al., 2003). Of recent note, the group
of P. G. Wang introduced a method to glycosylate proteins
with maltose- and dextrose-based polysaccharides as an
alternative to conjugation with polyethyleneglycol (PEG), which
is not as readily biodegradable (Styslinger et al., 2012). Clinical
applications for this burgeoning field are on the near horizon as
the techniques for protein conjugation as well as chemical and
enzymatic glycan synthesis become more advanced and readily
scalable.
Cell Surface Glycoengineering Offers Distinct Modes
of Control and Targeting
While efforts in glycan engineering and remodeling have focused
on glycans on proteins or as small molecules, many glycan-
protein interactions in biology occur at cellular interfaces.
Thus, there is a need for tools that can monitor or regulate the
density of specific glycan structures in the context of cellular sur-
faces to better understand and control the biological response.
In 1992, Reutter and colleagues took a step in this direction
when they demonstrated that administering the monosaccha-
ride derivative, N-propanoyl-D-mannosamine, to rats led to the
subsequent incorporation of N-propanoyl-sialic acids into their
cellular membranes and serum glycoproteins (Kayser et al.,
1992). This notion of cell surface glycan remodeling was further
established by the Bertozzi group, which developed metabolic
oligosaccharide engineering (MOE) (Boyce and Bertozzi, 2011;
Luchansky et al., 2003). This methodology has expanded the
chemical space of the glycome to introduce ketone, azide, thiol,
and alkyne functional groups into the glycans of cells and living
animals (Figure 7; Laughlin and Bertozzi, 2009).
Beyond its use for imaging and analyzing glycans (Agard and
Bertozzi, 2009), MOE can also be used for targeting specific gly-
cans in therapeutic endeavors. Immunization of rabbits with a
ketone-containing sialic acid bound to the carrier KLH produced
significant titers of antibodies that were specific for this unnatural
sialic acid moiety (Lemieux and Bertozzi, 2001). The antibodies
were capable of binding to cancer cells that were fed the unnat-
ural biosynthetic precursor and could successfully promote their
eradication through complement-mediated lysis. This approach
to target cancer has also been shown with N-propionyl-mannos-
amine which was incorporated into leukemic cell surface poly-
sialic acids as N-propionylpolysialic acid. Cell death could then
be induced by treatment with a specific antibody against a2-8-
N-propionylated polysialic acid (Liu et al., 2000). Further efforts
in this direction are being pursued by the Guo research group
to increase the immunogenicity of specific TACAs for cancer
immunotherapy (Wang et al., 2007, 2008a).ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 27
Figure 7. Modified Monosaccharides that Can Be Incorporated via Metabolic Oligosaccharide Engineering Display a Range of Functional
Groups on the Cell Surface
Four modified monosaccharides have been incorporated into vertebrate glycans (Neu5Ac, GalNAc, GlcNAc, and fucose), which contain handles for chemo-
selective reactions or photoaffinity tags.
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(Figure 7), a bioorthogonal reaction strategy has also been em-
ployed to target the pathogen Helicobacter pylori (Kaewsapsak
et al., 2013). By feeding the bacteria an azide containing N-ace-
tylglucosamine (GlcNAz), which is incorporated more efficiently
into bacterial than mammalian cell surfaces, the azide on the
H. pylori could be labeled with a 2,4-dinitrophenyl (DNP) phos-
phine by the Staudinger ligation (Saxon and Bertozzi, 2000).
The H. pylori could then be eliminated by binding to naturally
found anti-DNP antibodies. Aside from antibody targeting, the
reactive functional groups of non-natural sugars can also target
drug delivery vehicles as has been demonstrated in the reaction
of hydrazide-coated nanoparticles with cell surface glycan
ketones (Iwasaki et al., 2007). Because many pathogens and tu-
mor cells display glycan structures not normally found on healthy
human tissue, one can imagine a slew of modalities to target
these epitopes via MOE.
MOE can also be used to engineer cell- and stem cell-based
therapies for regeneration and disease studies (Du and Yarema,
2010). In fact, many stem cell markers are glycans such as the
stage specific embryonic antigens SSEA-1, -3, and -4 or heavily
glycosylatedmucins such as CD34 (Muramatsu andMuramatsu,
2004). The field of cell therapy is quickly expanding to include an
array of therapeutic applications utilizing donor cells ranging
from stem cell progenitors to terminally differentiated tissues
(Stephan and Irvine, 2011). As a testament to their increasing
therapeutic value, there are currently over 500 companies based
on cell-based therapies and products (Kirouac and Zandstra,
2008). Bioengineering methods such as MOE can play a large
role to increase their safety and efficacy.
In the late 1990s, N-propanoyl sialic acid incorporated into the
glycoproteins of cells from neonatal rat brains was shown to
stimulate the proliferation of astrocytes and microglia but not
of oligodendrocyte progenitors (Schmidt et al., 1998). The28 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rsame treatment was also shown to stimulate neurite outgrowth
in cerebellar neurons (Bu¨ttner et al., 2002). The Yarema research
group has utilized a thiol-containing mannosamine derivative to
install thiols into surface displayed sialic acids. When stem cells
bearing these cell surface thiols were grown on a gold surface,
the strong gold-thiol bonds that formed induced the stem cells
to adopt a neuron-like morphology and accumulate b-catenin,
a marker in neuronal differentiation (Sampathkumar et al.,
2006). Bertozzi and Gartner have also used the reaction with
azide bearing sugars to install DNA on cell surfaces (Gartner
and Bertozzi, 2009). By installing complementary DNA strands
on different cell types, they were able to assemble defined mi-
crotissues that can be used for studying disease progression
or organ development.
Other approaches in cell surface engineering have used
biochemical techniques to introduce specific glycan structures
onto cell surfaces to control their behavior and localization. In
a key example, the Sackstein group identified that hematopoiet-
ic stem cells (HSCs) expressed a CD44 glycoform (HCELL) that
contained sLex, which enabled HSCs to home to the bone
marrow via binding to endotheial E-selectin (Dimitroff et al.,
2001). The McEver group further demonstrated that human
cord blood can home significantly better to the bone marrow
upon treatment with exogenous a1-3 fucosyltransferase VI
which increased cell surface sLex and thus selectin binding
(Xia et al., 2004). The Sackstein group followed up on this study
by treating mesenchymal stem cells (MSCs) with a1-3 fucosyl-
transferase VI, which introduced the sLex CD44 glycoform,
HCELL, onto the MSCs (Figure 8A; Sackstein, 2012; Sackstein
et al., 2008). These HCELL-engineered human MSCs demon-
strated efficient homing to bonemarrow; a process that was pre-
viously a limiting factor in MSC-based treatments for bone and
cartilage diseases. In a similar approach, the Karp research
group has decorated cell surfaces with biotin, which can beights reserved
Figure 8. Cell Surface Glycoengineering
Glycosylation can be modified by exogenous enzymes (A) or materials (B and C) to alter glycosylation status for various functions. Cells with increased surface
sLex bind to the selectins, which increase rolling along the endothelium or increase the efficiency for bone marrow homing (A and B). Additionally, glycocalyx
engineering with cell surface-integrating sialic acid polymers can be used to protect cells from NK cell-mediated cytotoxicity (C).
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Reviewsubsequently functionalized with a biotinylated sialyl Lewisx
through a streptavidin bridge (Figure 8B; Sarkar et al., 2008,
2010). The glycoengineered cells showed enhanced binding to
selectins and initiated rolling on activated endothelium. Mesen-
chymal stem cells engineered in this manner were able to
home to inflamed tissue in a mouse (Sarkar et al., 2011).
In addition to introducing specific carbohydrate structures
onto the cell surface, the removal of glycan epitopes has also
garnered interest in therapeutic applications. A paramount
example is the continuing endeavor to create universal blood
through the removal of the group A and B blood antigens. Early
pursuits in the 1980s identified an a-galactosaminidase from the
coffee bean that could convert group BRBCs to theOblood type
(Goldstein et al., 1982). While the converted blood proved
safe and effective in human trials, a low pH optimum and the
required grams of enzyme per blood unit hampered advances
to the clinic (Kruskall et al., 2000). A collaboration between the
laboratories of Henrissat and Clausen led to the identification
of two new bacterial glycosidase gene families that remove
group A (GalNAc) and B (Gal) antigens from the underlying H an-
tigen core on human red blood cells (RBCs; Liu et al., 2007).
Treatment of group A RBCs with an a-N-acetylgalactosamini-Chemistry & Bioldase from E. meningosepticum and group B RBCs with an
a-galactosaminidase from B. fragilis produced an O antigen
blood type while maintaining RBC viability and activity.
While impressive, these previous techniques cannot introduce
structurally defined glycans or control their density on cell sur-
faces. Yarema and Bertozzi previously showed that MOE could
be used to glycoengineer cell surfaces by reaction with synthetic
aminooxy glycans (Yarema et al., 1998). This approach, howev-
er, only added glycans onto randomly distributed cell surface
glycoproteins and potentially obscured natural glycan epitopes.
In an effort to emulate natural multivalent glycoproteins, the
Bertozzi group developed a platform to engineer a cell’s glyco-
calyx with synthetic glycans by generating glycopolymers end-
functionalized with phospholipids that could passively insert
into cell membranes (Rabuka et al., 2008). This technique en-
ables the introduction of chemically defined glycan structures
onto live cell surfaces, which is demanding to achieve through
conventional biological methods alone. This platform was
recently used to elucidate the roles of specific sialosides inmedi-
ating Siglec-based immunoevasion. A panel of sialylated glyco-
polymers was designed that could engage Siglecs on natural
killer (NK) cells and control NK-mediated cytotoxicity againstogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 29
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Reviewcancer cells (Figure 8C; Hudak et al., 2013). This aided in defining
a mechanism of cancer immunoevasion in which cancer hyper-
sialylation can protect against NK cell recognition and activation.
Themost efficacious of these polymers could alsomask xenoge-
neic porcine and allogeneic bone marrow cells from NK cell
killing for applications in cell-based transplantation.
Conclusions
Eighty years ago, the structure of the DNA double helix was
solved and ushered in a new era of biology. The ability to
sequence and alter the genetic code is reaching its technological
pinnacle and changing the way we approach treating disease.
This is now also true for the glycocode. Much like genomic
technology has enabled protein engineering (Brannigan and
Wilkinson, 2002), the same can now be said for glycoengineer-
ing. Through advances in physical and biological chemistry,
the glycobiology field now has the tools necessary to decipher
the sequence and the structure of cell- and protein-associated
glycans. Furthermore, cellular biologists and chemists have es-
tablished novel ways in which we can alter and exploit glycan
structure function. As this field has matured, it has become
obvious that the biomedical community can no longer ignore
the details of glycosylation. Glycans are ubiquitous and the abil-
ity to understand and control their functions are going to be vital
to pioneering future biological and therapeutic breakthroughs.
ACKNOWLEDGMENTS
We would like to thank Brian Belardi and Carolyn Hudak for helpful discussion
and critique of the manuscript. This work was funded by a grant from the US
National Institutes of Health (R01 GM59907). J.E.H. was supported by a pre-
doctoral fellowship from the US National Science Foundation.
REFERENCES
Abian, O., Alfonso, P., Velazquez-Campoy, A., Giraldo, P., Pocovi, M., and
Sancho, J. (2011). Therapeutic strategies for Gaucher disease: miglustat
(NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the
different thermostability of velaglucerase alfa and imiglucerase. Mol. Pharm.
8, 2390–2397.
Agard, N.J., and Bertozzi, C.R. (2009). Chemical approaches to perturb, pro-
file, and perceive glycans. Acc. Chem. Res. 42, 788–797.
Alley, W.R., Jr., Mann, B.F., and Novotny, M.V. (2013). High-sensitivity analyt-
ical approaches for the structural characterization of glycoproteins. Chem.
Rev. 113, 2668–2732.
Amano, K., Chiba, Y., Kasahara, Y., Kato, Y., Kaneko, M.K., Kuno, A., Ito, H.,
Kobayashi, K., Hirabayashi, J., Jigami, Y., and Narimatsu, H. (2008). Engineer-
ing of mucin-type human glycoproteins in yeast cells. Proc. Natl. Acad. Sci.
USA 105, 3232–3237.
Ametamey, S.M., Honer, M., and Schubiger, P.A. (2008). Molecular imaging
with PET. Chem. Rev. 108, 1501–1516.
Anthony, R.M., Nimmerjahn, F., Ashline, D.J., Reinhold, V.N., Paulson, J.C.,
and Ravetch, J.V. (2008). Recapitulation of IVIG anti-inflammatory activity
with a recombinant IgG Fc. Science 320, 373–376.
Apweiler, R., Hermjakob, H., and Sharon, N. (1999). On the frequency of pro-
tein glycosylation, as deduced from analysis of the SWISS-PROT database.
Biochim. Biophys. Acta 1473, 4–8.
Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M., and Dwek, R.A. (2007).
The impact of glycosylation on the biological function and structure of human
immunoglobulins. Annu. Rev. Immunol. 25, 21–50.
Asano, N. (2003). Glycosidase inhibitors: update and perspectives on practical
use. Glycobiology 13, 93R–104R.30 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rAstronomo, R.D., Lee, H.-K., Scanlan, C.N., Pantophlet, R., Huang, C.-Y., Wil-
son, I.A., Blixt, O., Dwek, R.A., Wong, C.-H., and Burton, D.R. (2008). A glyco-
conjugate antigen based on the recognition motif of a broadly neutralizing
human immunodeficiency virus antibody, 2G12, is immunogenic but elicits an-
tibodies unable to bind to the self glycans of gp120. J. Virol. 82, 6359–6368.
Aussedat, B., Vohra, Y., Park, P.K., Ferna´ndez-Tejada, A., Alam, S.M., Denni-
son, S.M., Jaeger, F.H., Anasti, K., Stewart, S., Blinn, J.H., et al. (2013). Chem-
ical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for
potential HIV-1-directed vaccines. J. Am. Chem. Soc. 135, 13113–13120.
Barocchi, M.A., Censini, S., and Rappuoli, R. (2007). Vaccines in the era of
genomics: the pneumococcal challenge. Vaccine 25, 2963–2973.
Becer, C.R. (2012). The glycopolymer code: synthesis of glycopolymers and
multivalent carbohydrate-lectin interactions. Macromol. Rapid Commun. 33,
742–752.
Becker, B., and Cooper, M.A. (2013). Aminoglycoside antibiotics in the 21st
century. ACS Chem. Biol. 8, 105–115.
Be´lot, F., Wright, K., Costachel, C., Phalipon, A., and Mulard, L.A. (2004).
Blockwise approach to fragments of the O-specific polysaccharide of Shigella
flexneri serotype 2a: convergent Synthesis of a decasaccharide representative
of a dimer of the branched repeating unit. J. Org. Chem. 69, 1060–1074.
Bennett, C.S., and Wong, C.-H. (2007). Chemoenzymatic approaches to
glycoprotein synthesis. Chem. Soc. Rev. 36, 1227–1238.
Bertozzi, C.R., and Kiessling, L.L. (2001). Chemical glycobiology. Science 291,
2357–2364.
Berzi, A., Reina, J.J., Ottria, R., Sutkeviciute, I., Antonazzo, P., Sanchez-
Navarro, M., Chabrol, E., Biasin, M., Trabattoni, D., Cetin, I., et al. (2012). A gly-
comimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and
cervical explant models. AIDS 26, 127–137.
Bettahi, I., Dasgupta, G., Renaudet, O., Chentoufi, A.A., Zhang, X., Carpenter,
D., Yoon, S., Dumy, P., and BenMohamed, L. (2009). Antitumor activity of a
self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+
T cell epitopes. Cancer Immunol. Immunother. 58, 187–200.
Bevilacqua, M., Butcher, E., Furie, B., Furie, B., Gallatin, M., Gimbrone, M.,
Harlan, J., Kishimoto, K., Lasky, L., McEver, R., et al. (1991). Selectins: a family
of adhesion receptors. Cell 67, 233.
Bishop, J.R., Schuksz, M., and Esko, J.D. (2007). Heparan sulphate proteogly-
cans fine-tune mammalian physiology. Nature 446, 1030–1037.
Blixt, O., Han, S., Liao, L., Zeng, Y., Hoffmann, J., Futakawa, S., and Paulson,
J.C. (2008). Sialoside analogue arrays for rapid identification of high affinity
siglec ligands. J. Am. Chem. Soc. 130, 6680–6681.
Boltje, T.J., Buskas, T., and Boons, G.-J. (2009). Opportunities and challenges
in synthetic oligosaccharide and glycoconjugate research. Nat. Chem. 1,
611–622.
Bond, M.R., and Hanover, J.A. (2013). O-GlcNAc cycling: a link betweenmeta-
bolism and chronic disease. Annu. Rev. Nutr. 33, 205–229.
Boons, G.-J. (2010). Bioorthogonal chemical reporter methodology for visual-
ization, isolation and analysis of glycoconjugates. Carbohydr. Chem. 36,
152–167.
Boyce, M., and Bertozzi, C.R. (2011). Bringing chemistry to life. Nat. Methods
8, 638–642.
Brannigan, J.A., and Wilkinson, A.J. (2002). Protein engineering 20 years on.
Nat. Rev. Mol. Cell Biol. 3, 964–970.
Brinkhous, K.M., Smith, H.P., Warner, E.D., and Seegers, W.H. (1939). The in-
hibition of blood clotting: an unidentified substance which acts in conjunction
with heparin to prevent the conversion of prothrombin into thrombin. Am. J.
Physiol. 125, 683–687.
Brown, J.R., Crawford, B.E., and Esko, J.D. (2007). Glycan antagonists and in-
hibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol. 42, 481–515.
Brown, J.M., Xia, J., Zhuang, B., Cho, K.-S., Rogers, C.J., Gama, C.I., Rawat,
M., Tully, S.E., Uetani, N., Mason, D.E., et al. (2012). A sulfated carbohydrate
epitope inhibits axon regeneration after injury. Proc. Natl. Acad. Sci. USA 109,
4768–4773.ights reserved
Chemistry & Biology
ReviewBundle, D.R., Nycholat, C., Costello, C., Rennie, R., and Lipinski, T. (2012).
Design of a Candida albicans disaccharide conjugate vaccine by reverse en-
gineering a protective monoclonal antibody. ACS Chem. Biol. 7, 1754–1763.
Busch, S.A., and Silver, J. (2007). The role of extracellular matrix in CNS regen-
eration. Curr. Opin. Neurobiol. 17, 120–127.
Buskas, T., Ingale, S., and Boons, G.-J. (2006). Glycopeptides as versatile
tools for glycobiology. Glycobiology 16, 113R–136R.
Bu¨ttner, B., Kannicht, C., Schmidt, C., Lo¨ster, K., Reutter,W., Lee, H.-Y., No¨hr-
ing, S., and Horstkorte, R. (2002). Biochemical engineering of cell surface sialic
acids stimulates axonal growth. J. Neurosci. 22, 8869–8875.
Castilho, A., Neumann, L., Daskalova, S., Mason, H.S., Steinkellner, H.,
Altmann, F., and Strasser, R. (2012). Engineering of sialylated mucin-type
O-glycosylation in plants. J. Biol. Chem. 287, 36518–36526.
Chabre, Y.M., and Roy, R. (2008). Recent trends in glycodendrimer syntheses
and applications. Curr. Top. Med. Chem. 8, 1237–1285.
Chalker, J.M., Bernardes, G.J.L., and Davis, B.G. (2011). A ‘‘tag-and-modify’’
approach to site-selective protein modification. Acc. Chem. Res. 44, 730–741.
Chang, P.V., and Bertozzi, C.R. (2012). Imaging beyond the proteome. Chem.
Commun. (Camb.) 48, 8864–8879.
Chang, J., Patton, J.T., Sarkar, A., Ernst, B., Magnani, J.L., and Frenette, P.S.
(2010). GMI-1070, a novel pan-selectin antagonist, reverses acute vascular
occlusions in sickle cell mice. Blood 116, 1779–1786.
Cheever, M.A., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht,
T.T., Mellman, I., Prindiville, S.A., Viner, J.L., Weiner, L.M., and Matrisian,
L.M. (2009). The prioritization of cancer antigens: a national cancer institute
pilot project for the acceleration of translational research. Clin. Cancer Res.
15, 5323–5337.
Chen, W.C., Completo, G.C., Sigal, D.S., Crocker, P.R., Saven, A., and Paul-
son, J.C. (2010). In vivo targeting of B-cell lymphoma with glycan ligands of
CD22. Blood 115, 4778–4786.
Chen, C., Constantinou, A., Chester, K.A., Vyas, B., Canis, K., Haslam, S.M.,
Dell, A., Epenetos, A.A., and Deonarain, M.P. (2012a). Glycoengineering
approach to half-life extension of recombinant biotherapeutics. Bioconjug.
Chem. 23, 1524–1533.
Chen, W.C., Kawasaki, N., Nycholat, C.M., Han, S., Pilotte, J., Crocker, P.R.,
and Paulson, J.C. (2012b). Antigen delivery to macrophages using liposomal
nanoparticles targeting sialoadhesin/CD169. PLoS ONE 7, e39039.
Choi, B.-K., Actor, J.K., Rios, S., d’Anjou, M., Stadheim, T.A., Warburton, S.,
Giaccone, E., Cukan, M., Li, H., Kull, A., et al. (2008). Recombinant human lac-
toferrin expressed in glycoengineered Pichia pastoris: effect of terminal
N-acetylneuraminic acid on in vitro secondary humoral immune response.
Glycoconj. J. 25, 581–593.
Cipolla, L., Peri, F., and Airoldi, C. (2008). Glycoconjugates in cancer therapy.
Anticancer. Agents Med. Chem. 8, 92–121.
Cipolla, L., Gregori, M., and So, P.-W. (2011). Glycans in magnetic resonance
imaging: determinants of relaxivity to smart agents, and potential applications
in biomedicine. Curr. Med. Chem. 18, 1002–1018.
Copeland, R., Balasubramaniam, A., Tiwari, V., Zhang, F., Bridges, A., Lin-
hardt, R.J., Shukla, D., and Liu, J. (2008). Using a 3-O-sulfated heparin octa-
saccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry
47, 5774–5783.
Creus, S., Chaia, Z., Pellizzari, E.H., Cigorraga, S.B., Ulloa-Aguirre, A., and
Campo, S. (2001). Human FSH isoforms: carbohydrate complexity as determi-
nant of in-vitro bioactivity. Mol. Cell. Endocrinol. 174, 41–49.
Crispin, M., Chang, V.T., Harvey, D.J., Dwek, R.A., Evans, E.J., Stuart, D.I.,
Jones, E.Y., Lord, J.M., Spooner, R.A., and Davis, S.J. (2009). A human embry-
onic kidney 293T cell line mutated at the Golgi alpha-mannosidase II locus.
J. Biol. Chem. 284, 21684–21695.
Cummings, R.D. (2009). The repertoire of glycan determinants in the human
glycome. Mol. Biosyst. 5, 1087–1104.
Datar, R.V., Cartwright, T., and Rosen, C.-G. (1993). Process economics of an-
imal cell and bacterial fermentations: a case study analysis of tissue plasmin-
ogen activator. Biotechnology (N. Y.) 11, 349–357.Chemistry & BiolDavies, J., Jiang, L., Pan, L.-Z., LaBarre, M.J., Anderson, D., and Reff, M.
(2001). Expression of GnTIII in a recombinant anti-CD20 CHO production
cell line: Expression of antibodies with altered glycoforms leads to an increase
in ADCC through higher affinity for FC g RIII. Biotechnol. Bioeng. 74, 288–294.
Davis, B.G., Lloyd, R.C., and Jones, J.B. (1998). Controlled Site-Selective
Glycosylation of Proteins by a Combined Site-Directed Mutagenesis and
Chemical Modification Approach. J. Org. Chem. 63, 9614–9615.
Deniaud, D., Julienne, K., andGouin, S.G. (2011). Insights in the rational design
of synthetic multivalent glycoconjugates as lectin ligands. Org. Biomol. Chem.
9, 966–979.
Dennis, J.W., Nabi, I.R., and Demetriou, M. (2009). Metabolism, cell surface or-
ganization, and disease. Cell 139, 1229–1241.
Dimitroff, C.J., Lee, J.Y., Rafii, S., Fuhlbrigge, R.C., and Sackstein, R. (2001).
CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.
J. Cell Biol. 153, 1277–1286.
Diot, J.D., Garcia Moreno, I., Twigg, G., Ortiz Mellet, C., Haupt, K., Butters,
T.D., Kovensky, J., and Gouin, S.G. (2011). Amphiphilic 1-deoxynojirimycin
derivatives through click strategies for chemical chaperoning in N370S
Gaucher cells. J. Org. Chem. 76, 7757–7768.
Dirksen, A., and Dawson, P.E. (2008). Expanding the scope of chemoselective
peptide ligations in chemical biology. Curr. Opin. Chem. Biol. 12, 760–766.
Dochez, A.R., and Avery, O.T. (1917). The elaboration of specific soluble sub-
stance by Pneumococcus during growth. J. Exp. Med. 26, 477–493.
Doores, K.J., Fulton, Z., Hong, V., Patel, M.K., Scanlan, C.N., Wormald, M.R.,
Finn, M.G., Burton, D.R., Wilson, I.A., and Davis, B.G. (2010). A nonself sugar
mimic of the HIV glycan shield shows enhanced antigenicity. Proc. Natl. Acad.
Sci. USA 107, 17107–17112.
Du, J., and Yarema, K.J. (2010). Carbohydrate engineered cells for regenera-
tive medicine. Adv. Drug Deliv. Rev. 62, 671–682.
Dwyer, J.M. (1992). Manipulating the immune system with immune globulin.
N. Engl. J. Med. 326, 107–116.
Egger, J., Weckerle, C., Cutting, B., Schwardt, O., Rabbani, S., Lemme, K.,
and Ernst, B. (2013). Nanomolar E-selectin antagonists with prolonged half-
lives by a fragment-based approach. J. Am. Chem. Soc. 135, 9820–9828.
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L.,
Chang, D., Fuller, J., Grant, J., et al. (2003). Enhancement of therapeutic pro-
tein in vivo activities through glycoengineering. Nat. Biotechnol. 21, 414–421.
Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.W., Coleman, T., Kreilgaard,
M., Torup, L., Sager, T., Erbayraktar, Z., Gokmen, N., et al. (2003). Asialoery-
thropoietin is a nonerythropoietic cytokine with broad neuroprotective activity
in vivo. Proc. Natl. Acad. Sci. USA 100, 6741–6746.
Ernst, B., and Magnani, J.L. (2009). From carbohydrate leads to glycomimetic
drugs. Nat. Rev. Drug Discov. 8, 661–677.
Ferrara, C., Grau, S., Ja¨ger, C., Sondermann, P., Bru¨nker, P., Waldhauer, I.,
Hennig, M., Ruf, A., Rufer, A.C., Stihle, M., et al. (2011). Unique carbohy-
drate-carbohydrate interactions are required for high affinity binding between
FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA
108, 12669–12674.
Ferreira, S.B., Sodero, A.C.R., Cardoso,M.F.C., Lima, E.S., Kaiser, C.R., Silva,
F.P., and Ferreira, V.F. (2010). Synthesis, biological activity, and molecular
modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as a-gluco-
sidases inhibitors. J. Med. Chem. 53, 2364–2375.
Fischer, E., and Bergmann, M. (1909). Untersuchungen Uber Kohlenhydrate
und Fermente. (Berlin: J. Springer).
Francis, T., and Tillett, W.S. (1930). Cutaneous reactions in pneumonia. the
development of antibodies following the intradermal injection of type-specific
polysaccharide. J. Exp. Med. 52, 573–585.
Fujita, K., and Yamamoto, K. (2006). A remodeling system for the oligosaccha-
ride chains on glycoproteins with microbial endo-beta-N-acetylglucosamini-
dases. Biochim. Biophys. Acta 1760, 1631–1635.
Fukuda, M. (1996). Possible roles of tumor-associated carbohydrate antigens.
Cancer Res. 56, 2237–2244.ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 31
Chemistry & Biology
ReviewFukuda, M.N., Sasaki, H., Lopez, L., and Fukuda, M. (1989). Survival of recom-
binant erythropoietin in the circulation: the role of carbohydrates. Blood 73,
84–89.
Gabius, H.-J., Siebert, H.-C., Andre´, S., Jime´nez-Barbero, J., and Ru¨diger, H.
(2004). Chemical biology of the sugar code. ChemBioChem 5, 740–764.
Gamblin, D.P., Scanlan, E.M., and Davis, B.G. (2009). Glycoprotein synthesis:
an update. Chem. Rev. 109, 131–163.
Garcı´a-Vallejo, J.J., Ambrosini, M., Overbeek, A., van Riel, W.E., Bloem, K.,
Unger, W.W.J., Chiodo, F., Bolscher, J.G., Nazmi, K., Kalay, H., and van
Kooyk, Y. (2013). Multivalent glycopeptide dendrimers for the targeted delivery
of antigens to dendritic cells. Mol. Immunol. 53, 387–397.
Gartner, Z.J., and Bertozzi, C.R. (2009). Programmed assembly of 3-dimen-
sional microtissues with defined cellular connectivity. Proc. Natl. Acad. Sci.
USA 106, 4606–4610.
Gening, M.L., Maira-Litra´n, T., Kropec, A., Skurnik, D., Grout, M., Tsvetkov,
Y.E., Nifantiev, N.E., and Pier, G.B. (2010). Synthetic b-(1->6)-linked N-acety-
lated and nonacetylated oligoglucosamines used to produce conjugate
vaccines for bacterial pathogens. Infect. Immun. 78, 764–772.
Gestwicki, J.E., Cairo, C.W., Strong, L.E., Oetjen, K.A., and Kiessling, L.L.
(2002). Influencing receptor-ligand binding mechanisms with multivalent
ligand architecture. J. Am. Chem. Soc. 124, 14922–14933.
Gilewski, T., Adluri, S., Ragupathi, G., Zhang, S., Yao, T.-J., Panageas, K.,
Moynahan, M., Houghton, A., Norton, L., and Livingston, P.O. (2000). Vaccina-
tion of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet
hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6, 1693–1701.
Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L.J., Musselli, C., Zhang, X.-F.,
Bornmann, W.G., Spassova, M., Bencsath, K.P., Panageas, K.S., et al. (2001).
Immunization of metastatic breast cancer patients with a fully synthetic globo
H conjugate: a phase I trial. Proc. Natl. Acad. Sci. USA 98, 3270–3275.
Goldstein, J., Siviglia, G., Hurst, R., Lenny, L., and Reich, L. (1982). Group B
erythrocytes enzymatically converted to group O survive normally in A, B,
and O individuals. Science 215, 168–170.
Grayson, E.J., Bernardes, G.J.L., Chalker, J.M., Boutureira, O., Koeppe, J.R.,
and Davis, B.G. (2011). A coordinated synthesis and conjugation strategy for
the preparation of homogeneous glycoconjugate vaccine candidates. Angew.
Chem. Int. Ed. Engl. 50, 4127–4132.
Haltiwanger, R.S., and Lowe, J.B. (2004). Role of glycosylation in develop-
ment. Annu. Rev. Biochem. 73, 491–537.
Hamilton, S.R., Davidson, R.C., Sethuraman, N., Nett, J.H., Jiang, Y., Rios, S.,
Bobrowicz, P., Stadheim, T.A., Li, H., Choi, B.-K., et al. (2006). Humanization of
yeast to produce complex terminally sialylated glycoproteins. Science 313,
1441–1443.
Hang, H.C., and Bertozzi, C.R. (2005). The chemistry and biology of mucin-
type O-linked glycosylation. Bioorg. Med. Chem. 13, 5021–5034.
Hanisch, F.-G. (2001). O-glycosylation of the mucin type. Biol. Chem. 382,
143–149.
Heidelberger, M., and Avery, O.T. (1923). The soluble specific substance of
Pneumococcus. J. Exp. Med. 38, 73–79.
Heidelberger, M., Dilapi, M.M., Siegel, M., and Walter, A.W. (1950). Persis-
tence of antibodies in human subjects injected with pneumococcal polysac-
charides. J. Immunol. 65, 535–541.
Hewitt, M.C., Snyder, D.A., and Seeberger, P.H. (2002). Rapid synthesis of a
glycosylphosphatidylinositol-based malaria vaccine using automated solid-
phase oligosaccharide synthesis. J. Am. Chem. Soc. 124, 13434–13436.
Hickman, S., and Kornfeld, S. (1978). Effect of tunicamycin on IgM, IgA, and
IgG secretion by mouse plasmacytoma cells. J. Immunol. 121, 990–996.
Hirano, K., Macmillan, D., Tezuka, K., Tsuji, T., and Kajihara, Y. (2009). Design
and synthesis of a homogeneous erythropoietin analogue with two human
complex-type sialyloligosaccharides: combined use of chemical and bacterial
protein expression methods. Angew. Chem. Int. Ed. Engl. 48, 9557–9560.
Hollingsworth, M.A., and Swanson, B.J. (2004). Mucins in cancer: protection
and control of the cell surface. Nat. Rev. Cancer 4, 45–60.32 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rHossler, P., Khattak, S.F., and Li, Z.J. (2009). Optimal and consistent protein
glycosylation in mammalian cell culture. Glycobiology 19, 936–949.
Huang, W., Li, C., Li, B., Umekawa, M., Yamamoto, K., Zhang, X., and Wang,
L.-X. (2009). Glycosynthases enable a highly efficient chemoenzymatic syn-
thesis of N-glycoproteins carrying intact natural N-glycans. J. Am. Chem.
Soc. 131, 2214–2223.
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., and Wang, L.-X. (2012a).
Chemoenzymatic glycoengineering of intact IgG antibodies for gain of func-
tions. J. Am. Chem. Soc. 134, 12308–12318.
Huang, Z.-H., Shi, L., Ma, J.-W., Sun, Z.-Y., Cai, H., Chen, Y.-X., Zhao, Y.-F.,
and Li, Y.-M. (2012b). A totally synthetic, self-assembling, adjuvant-freeMUC1
glycopeptide vaccine for cancer therapy. J. Am. Chem. Soc. 134, 8730–8733.
Huang, Y.-L., Hung, J.-T., Cheung, S.K.C., Lee, H.-Y., Chu, K.-C., Li, S.-T., Lin,
Y.-C., Ren, C.-T., Cheng, T.-J.R., Hsu, T.-L., et al. (2013). Carbohydrate-based
vaccines with a glycolipid adjuvant for breast cancer. Proc. Natl. Acad. Sci.
USA 110, 2517–2522.
Hudak, J.E., Yu, H.H., and Bertozzi, C.R. (2011). Protein glycoengineering
enabled by the versatile synthesis of aminooxy glycans and the genetically en-
coded aldehyde tag. J. Am. Chem. Soc. 133, 16127–16135.
Hudak, J.E., Canham, S.M., and Bertozzi, C.R. (2013). Glycocalyx engineering
reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem.
Biol. Published online November 24, 2013. http://dx.doi.org/10.1038/
nchembio.1388.
Humphries, D.E., Wong, G.W., Friend, D.S., Gurish, M.F., Qiu, W.-T., Huang,
C., Sharpe, A.H., and Stevens, R.L. (1999). Heparin is essential for the storage
of specific granule proteases in mast cells. Nature 400, 769–772.
Imberty, A., Chabre, Y.M., and Roy, R. (2008). Glycomimetics and glycoden-
drimers as high affinity microbial anti-adhesins. Chemistry 14, 7490–7499.
Imhof, B.A., and Aurrand-Lions, M. (2004). Adhesion mechanisms regulating
the migration of monocytes. Nat. Rev. Immunol. 4, 432–444.
Ingale, S., Wolfert, M.A., Gaekwad, J., Buskas, T., and Boons, G.-J. (2007).
Robust immune responses elicited by a fully synthetic three-component
vaccine. Nat. Chem. Biol. 3, 663–667.
Iwasaki, Y., Maie, H., and Akiyoshi, K. (2007). Cell-specific delivery of poly-
meric nanoparticles to carbohydrate-tagging cells. Biomacromolecules 8,
3162–3168.
Jacobs, P.P., Geysens, S., Vervecken, W., Contreras, R., and Callewaert, N.
(2009). Engineering complex-type N-glycosylation in Pichia pastoris using
GlycoSwitch technology. Nat. Protoc. 4, 58–70.
Jandus, C., Simon, H.-U., and von Gunten, S. (2011). Targeting siglecs—a
novel pharmacological strategy for immuno- and glycotherapy. Biochem.
Pharmacol. 82, 323–332.
Jefferis, R. (2009). Glycosylation as a strategy to improve antibody-based ther-
apeutics. Nat. Rev. Drug Discov. 8, 226–234.
Jefferis, R. (2012). Isotype and glycoform selection for antibody therapeutics.
Arch. Biochem. Biophys. 526, 159–166.
Joyce, J.G., Krauss, I.J., Song, H.C., Opalka, D.W., Grimm, K.M., Nahas, D.D.,
Esser, M.T., Hrin, R., Feng, M., Dudkin, V.Y., et al. (2008). An oligosaccharide-
based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific anti-
bodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. USA 105,
15684–15689.
Ju, T., Otto, V.I., and Cummings, R.D. (2011). The Tn antigen-structural
simplicity and biological complexity. Angew. Chem. Int. Ed. Engl. 50, 1770–
1791.
Julien, J.-P., Lee, J.H., Cupo, A., Murin, C.D., Derking, R., Hoffenberg, S.,
Caulfield, M.J., King, C.R., Marozsan, A.J., Klasse, P.J., et al. (2013). Asym-
metric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.
Proc. Natl. Acad. Sci. USA 110, 4351–4356.
Kabat, E.A., and Leskowitz, S. (1955). Immunochemical studies on blood
groups. XVII. structural units involved in blood group A and B specificity1.
J. Am. Chem. Soc. 77, 5159–5164.ights reserved
Chemistry & Biology
ReviewKaewsapsak, P., Esonu, O., and Dube, D.H. (2013). Recruiting the host’s im-
mune system to target Helicobacter pylori’s surface glycans. ChemBioChem
14, 721–726.
Kaneko, Y., Nimmerjahn, F., and Ravetch, J.V. (2006). Anti-inflammatory activ-
ity of immunoglobulin G resulting from Fc sialylation. Science 313, 670–673.
Karsten, C.M., Pandey, M.K., Figge, J., Kilchenstein, R., Taylor, P.R., Rosas,
M., McDonald, J.U., Orr, S.J., Berger, M., Petzold, D., et al. (2012). Anti-inflam-
matory activity of IgG1 mediated by Fc galactosylation and association of
FcgRIIB and dectin-1. Nat. Med. 18, 1401–1406.
Kayser, H., Zeitler, R., Kannicht, C., Grunow, D., Nuck, R., and Reutter, W.
(1992). Biosynthesis of a nonphysiological sialic acid in different rat organs,
using N-propanoyl-D-hexosamines as precursors. J. Biol. Chem. 267,
16934–16938.
Kelloff, G.J., Hoffman, J.M., Johnson, B., Scher, H.I., Siegel, B.A., Cheng, E.Y.,
Cheson, B.D., O’shaughnessy, J., Guyton, K.Z., Mankoff, D.A., et al. (2005).
Progress and promise of FDG-PET imaging for cancer patient management
and oncologic drug development. Clin. Cancer Res. 11, 2785–2808.
Kerr, K.M., Auger, W.R., Marsh, J.J., Comito, R.M., Fedullo, R.L., Smits, G.J.,
Kapelanski, D.P., Fedullo, P.F., Channick, R.N., Jamieson, S.W., and Moser,
K.M. (2000). The use of cylexin (CY-1503) in prevention of reperfusion lung
injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Re-
spir. Crit. Care Med. 162, 14–20.
Kiessling, L.L., andGrim, J.C. (2013). Glycopolymer probes of signal transduc-
tion. Chem. Soc. Rev. 42, 4476–4491.
Kikkeri, R., Lepenies, B., Adibekian, A., Laurino, P., and Seeberger, P.H.
(2009). In vitro imaging and in vivo liver targeting with carbohydrate capped
quantum dots. J. Am. Chem. Soc. 131, 2110–2112.
Kim, J.-H., Resende, R., Wennekes, T., Chen, H.-M., Bance, N., Buchini, S.,
Watts, A.G., Pilling, P., Streltsov, V.A., Petric, M., et al. (2013). Mechanism-
based covalent neuraminidase inhibitors with broad-spectrum influenza anti-
viral activity. Science 340, 71–75.
Kirouac, D.C., and Zandstra, P.W. (2008). The systematic production of cells
for cell therapies. Cell Stem Cell 3, 369–381.
Kitov, P.I., Sadowska, J.M., Mulvey, G., Armstrong, G.D., Ling, H., Pannu,
N.S., Read, R.J., and Bundle, D.R. (2000). Shiga-like toxins are neutralized
by tailored multivalent carbohydrate ligands. Nature 403, 669–672.
Kitov, P.I., Mulvey, G.L., Griener, T.P., Lipinski, T., Solomon, D., Paszkiewicz,
E., Jacobson, J.M., Sadowska, J.M., Suzuki, M., Yamamura, K., et al. (2008).
In vivo supramolecular templating enhances the activity of multivalent ligands:
a potential therapeutic against the Escherichia coli O157 AB5 toxins. Proc.
Natl. Acad. Sci. USA 105, 16837–16842.
Kloppel, T.M., Keenan, T.W., Freeman, M.J., and Morre´, D.J. (1977). Glyco-
lipid-bound sialic acid in serum: increased levels in mice and humans bearing
mammary carcinomas. Proc. Natl. Acad. Sci. USA 74, 3011–3013.
Kogan, T.P., Dupre´, B., Bui, H., McAbee, K.L., Kassir, J.M., Scott, I.L., Hu, X.,
Vanderslice, P., Beck, P.J., and Dixon, R.A. (1998). Novel synthetic inhibitors
of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethyl-
phenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269). J. Med.
Chem. 41, 1099–1111.
Kruskall, M.S., AuBuchon, J.P., Anthony, K.Y., Herschel, L., Pickard, C., Biehl,
R., Horowitz, M., Brambilla, D.J., and Popovsky, M.A. (2000). Transfusion to
blood group A and O patients of group B RBCs that have been enzymatically
converted to group O. Transfusion 40, 1290–1298.
Kufe, D.W. (2009). Mucins in cancer: function, prognosis and therapy. Nat.
Rev. Cancer 9, 874–885.
La Ferla, B., Airoldi, C., Zona, C., Orsato, A., Cardona, F., Merlo, S., Sironi, E.,
D’Orazio, G., and Nicotra, F. (2011). Natural glycoconjugates with antitumor
activity. Nat. Prod. Rep. 28, 630–648.
Lairson, L.L., Henrissat, B., Davies, G.J., and Withers, S.G. (2008). Glycosyl-
transferases: structures, functions, and mechanisms. Annu. Rev. Biochem.
77, 521–555.
Lakshminarayanan, V., Thompson, P.,Wolfert, M.A., Buskas, T., Bradley, J.M.,
Pathangey, L.B., Madsen, C.S., Cohen, P.A., Gendler, S.J., and Boons, G.-J.
(2012). Immune recognition of tumor-associatedmucinMUC1 is achieved by aChemistry & Biolfully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl.
Acad. Sci. USA 109, 261–266.
Landsteiner, K. (1900). Zur Kenntnis der antifermentativen, lytischen und
agglutinierenden Wirkungen des Blutserums und der Lymphe. Zentralbl.
Bakteriol. 27, 357–362.
Lasky, L.A. (1995). Selectin-carbohydrate interactions and the initiation of the
inflammatory response. Annu. Rev. Biochem. 64, 113–139.
Laughlin, S.T., and Bertozzi, C.R. (2009). Imaging the glycome. Proc. Natl.
Acad. Sci. USA 106, 12–17.
Lee, D.J., Mandal, K., Harris, P.W.R., Brimble, M.A., and Kent, S.B.H. (2009). A
one-pot approach to neoglycopeptides using orthogonal native chemical liga-
tion and click chemistry. Org. Lett. 11, 5270–5273.
Lemieux, G.A., and Bertozzi, C.R. (2001). Modulating cell surface immunore-
activity by metabolic induction of unnatural carbohydrate antigens. Chem.
Biol. 8, 265–275.
Lepenies, B., Yin, J., and Seeberger, P.H. (2010). Applications of synthetic car-
bohydrates to chemical biology. Curr. Opin. Chem. Biol. 14, 404–411.
Lever, R., Mulloy, B., and Page, C.P. (2012). Heparin: A Century of Progress.
(Berlin: Springer).
Li, H., Sethuraman, N., Stadheim, T.A., Zha, D., Prinz, B., Ballew, N., Bobro-
wicz, P., Choi, B.-K., Cook, W.J., Cukan, M., et al. (2006). Optimization of
humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24,
210–215.
Li, J., Dong, S., Townsend, S.D., Dean, T., Gardella, T.J., andDanishefsky, S.J.
(2012). Chemistry as an expanding resource in protein science: fully synthetic
and fully active human parathyroid hormone-related protein (1-141). Angew.
Chem. Int. Ed. Engl. 51, 12263–12267.
Liang, P.-H., Wu, C.-Y., Greenberg, W.A., and Wong, C.-H. (2008). Glycan ar-
rays: biological and medical applications. Curr. Opin. Chem. Biol. 12, 86–92.
Lin, R., Rosahl, T.W., Whiting, P.J., Fawcett, J.W., and Kwok, J.C.F. (2011).
6-Sulphated chondroitins have a positive influence on axonal regeneration.
PLoS ONE 6, e21499.
Lindahl, U., Ba¨ckstro¨m, G., Ho¨o¨k, M., Thunberg, L., Fransson, L.A., and Linker,
A. (1979). Structure of the antithrombin-binding site in heparin. Proc. Natl.
Acad. Sci. USA 76, 3198–3202.
Lindahl, U., Ba¨ckstro¨m, G., Thunberg, L., and Leder, I.G. (1980). Evidence for a
3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of
heparin. Proc. Natl. Acad. Sci. USA 77, 6551–6555.
Linhardt, R.J. (2003). 2003 Claude S. Hudson Award address in carbohydrate
chemistry. Heparin: structure and activity. J. Med. Chem. 46, 2551–2564.
Lipinski, T., Kitov, P.I., Szpacenko, A., Paszkiewicz, E., and Bundle, D.R.
(2011). Synthesis and immunogenicity of a glycopolymer conjugate.
Bioconjug. Chem. 22, 274–281.
Liu, T., Guo, Z., Yang, Q., Sad, S., and Jennings, H.J. (2000). Biochemical en-
gineering of surface alpha 2-8 polysialic acid for immunotargeting tumor cells.
J. Biol. Chem. 275, 32832–32836.
Liu, H., Wang, L., Brock, A., Wong, C.H., and Schultz, P.G. (2003). A method
for the generation of glycoprotein mimetics. J. Am. Chem. Soc. 125, 1702–
1703.
Liu, Q.P., Sulzenbacher, G., Yuan, H., Bennett, E.P., Pietz, G., Saunders, K.,
Spence, J., Nudelman, E., Levery, S.B., White, T., et al. (2007). Bacterial glyco-
sidases for the production of universal red blood cells. Nat. Biotechnol. 25,
454–464.
Liu, H., Zhang, Z., and Linhardt, R.J. (2009). Lessons learned from the contam-
ination of heparin. Nat. Prod. Rep. 26, 313–321.
Luchansky, S.J., Hang, H.C., Saxon, E., Grunwell, J.R., Yu, C., Dube, D.H., and
Bertozzi, C.R. (2003). Constructing azide-labeled cell surfaces using polysac-
charide biosynthetic pathways. Methods Enzymol. 362, 249–272.
Lundquist, J.J., and Toone, E.J. (2002). The cluster glycoside effect. Chem.
Rev. 102, 555–578.ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 33
Chemistry & Biology
ReviewMaccarana, M., and Lindahl, U. (1993). Mode of interaction between platelet
factor 4 and heparin. Glycobiology 3, 271–277.
MacLeod, C.M., Hodges, R.G., Heidelberger, M., and Bernhard, W.G. (1945).
Prevention of Pneumococcal Pneumonia by Immunization with Specific
Capsular Polysaccharides. J. Exp. Med. 82, 445–465.
Malhotra, R., Wormald, M.R., Rudd, P.M., Fischer, P.B., Dwek, R.A., and Sim,
R.B. (1995). Glycosylation changes of IgG associated with rheumatoid arthritis
can activate complement via the mannose-binding protein. Nat. Med. 1,
237–243.
Marradi, M., Chiodo, F., Garcı´a, I., and Penade´s, S. (2013). Glyconanoparticles
asmultifunctional andmultimodal carbohydrate systems. Chem. Soc. Rev. 42,
4728–4745.
Marth, J.D. (2008). A unified vision of the building blocks of life. Nat. Cell Biol.
10, 1015–1016.
Martı´nez-Avila, O., Bedoya, L.M., Marradi, M., Clavel, C., Alcamı´, J., and
Penade´s, S. (2009). Multivalent manno-glyconanoparticles inhibit DC-SIGN-
mediated HIV-1 trans-infection of human T cells. ChemBioChem 10, 1806–
1809.
Matrosovich, M.N., Matrosovich, T.Y., Gray, T., Roberts, N.A., and Klenk,
H.-D. (2004). Neuraminidase is important for the initiation of influenza virus
infection in human airway epithelium. J. Virol. 78, 12665–12667.
McCoy, L.E., and Weiss, R.A. (2013). Neutralizing antibodies to HIV-1 induced
by immunization. J. Exp. Med. 210, 209–223.
McLean, J. (1916). The Thromboplastic Action of Cephalin. Am. J. Physiol. 41,
250–257.
Mintzer, M.A., Dane, E.L., O’Toole, G.A., and Grinstaff, M.W. (2012). Exploiting
dendrimer multivalency to combat emerging and re-emerging infectious dis-
eases. Mol. Pharm. 9, 342–354.
Mohanty, A.K., Misra, M., and Hinrichsen, G. (2000). Biofibres, biodegradable
polymers and biocomposites: An overview. Macromol. Mater. Eng. 276-277,
1–24.
Morelli, L., Poletti, L., and Lay, L. (2011). Carbohydrates and Immunology:
Synthetic Oligosaccharide Antigens for Vaccine Formulation. Eur. J. Org.
Chem. 2011, 5723–5777.
Morgan, W.T.J., and Watkins, W.M. (1953). The inhibition of the haemaggluti-
nins in plant seeds by human blood group substances and simple sugars. Br.
J. Exp. Pathol. 34, 94–103.
Muramatsu, T., and Muramatsu, H. (2004). Carbohydrate antigens expressed
on stem cells and early embryonic cells. Glycoconj. J. 21, 41–45.
Muthana, S.M., Campbell, C.T., and Gildersleeve, J.C. (2012). Modifications of
glycans: biological significance and therapeutic opportunities. ACS Chem.
Biol. 7, 31–43.
Nagorny, P., Fasching, B., Li, X., Chen, G., Aussedat, B., and Danishefsky, S.J.
(2009). Toward fully synthetic homogeneous beta-human follicle-stimulating
hormone (beta-hFSH) with a biantennary N-linked dodecasaccharide. synthe-
sis of beta-hFSH with chitobiose units at the natural linkage sites. J. Am.
Chem. Soc. 131, 5792–5799.
Nagorny, P., Sane, N., Fasching, B., Aussedat, B., and Danishefsky, S.J.
(2012). Probing the frontiers of glycoprotein synthesis: the fully elaborated
b-subunit of the human follicle-stimulating hormone. Angew. Chem. Int. Ed.
Engl. 51, 975–979.
Newkome, G.R., and Shreiner, C.D. (2008). Poly(amidoamine), polypropyleni-
mine, and related dendrimers and dendrons possessing different 1 / 2
branching motifs: An overview of the divergent procedures. Polymer (Guildf.)
49, 1–173.
Newkome, G.R., and Shreiner, C. (2010). Dendrimers derived from 1 / 3
branching motifs. Chem. Rev. 110, 6338–6442.
Nimmerjahn, F., and Ravetch, J.V. (2005). Divergent immunoglobulin g sub-
class activity through selective Fc receptor binding. Science 310, 1510–1512.
North, S.J., Huang, H.-H., Sundaram, S., Jang-Lee, J., Etienne, A.T., Trollope,
A., Chalabi, S., Dell, A., Stanley, P., and Haslam, S.M. (2010). Glycomics
profiling of Chinese hamster ovary cell glycosylation mutants reveals N-gly-
cans of a novel size and complexity. J. Biol. Chem. 285, 5759–5775.34 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rNose, M., and Wigzell, H. (1983). Biological significance of carbohydrate
chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80, 6632–6636.
Nycholat, C.M., Rademacher, C., Kawasaki, N., and Paulson, J.C. (2012). In
silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of
macrophages. J. Am. Chem. Soc. 134, 15696–15699.
O’Reilly, M.K., and Paulson, J.C. (2009). Siglecs as targets for therapy in im-
mune-cell-mediated disease. Trends Pharmacol. Sci. 30, 240–248.
Ohtsubo, K., and Marth, J.D. (2006). Glycosylation in cellular mechanisms of
health and disease. Cell 126, 855–867.
Ohyanagi, T., Nagahori, N., Shimawaki, K., Hinou, H., Yamashita, T., Sasaki,
A., Jin, T., Iwanaga, T., Kinjo, M., and Nishimura, S.-I. (2011). Importance of
sialic acid residues illuminated by live animal imaging using phosphorylcholine
self-assembled monolayer-coated quantum dots. J. Am. Chem. Soc. 133,
12507–12517.
Okeley, N.M., Alley, S.C., Anderson, M.E., Boursalian, T.E., Burke, P.J., Em-
merton, K.M., Jeffrey, S.C., Klussman, K., Law, C.-L., Sussman, D., et al.
(2013). Development of orally active inhibitors of protein and cellular fucosyla-
tion. Proc. Natl. Acad. Sci. USA 110, 5404–5409.
Ostash, B., Yan, X., Fedorenko, V., andBechthold, A. (2010). Chemoenzymatic
and bioenzymatic synthesis of carbohydrate containing natural products. Top.
Curr. Chem. 297, 105–148.
Ouerfelli, O., Warren, J.D., Wilson, R.M., and Danishefsky, S.J. (2005). Syn-
thetic carbohydrate-based antitumor vaccines: challenges and opportunities.
Expert Rev. Vaccines 4, 677–685.
Pang, P.-C., Chiu, P.C.N., Lee, C.-L., Chang, L.-Y., Panico, M., Morris, H.R.,
Haslam, S.M., Khoo, K.-H., Clark, G.F., Yeung, W.S.B., and Dell, A. (2011). Hu-
man sperm binding is mediated by the sialyl-Lewis(x) oligosaccharide on the
zona pellucida. Science 333, 1761–1764.
Parker, R.B., and Kohler, J.J. (2010). Regulation of intracellular signaling by
extracellular glycan remodeling. ACS Chem. Biol. 5, 35–46.
Pashov, A., Monzavi-Karbassi, B., and Kieber-Emmons, T. (2011). Glycan
mediated immune responses to tumor cells. Hum. Vaccin. 7 (Suppl ), 156–165.
Pastores, G.M. (2010). Recombinant glucocerebrosidase (imiglucerase) as a
therapy for Gaucher disease. BioDrugs 24, 41–47.
Pejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.-S., Wang, S.-K.,
Stanfield, R.L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011). A potent and
broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Science 334, 1097–1103.
Perlman, S., van den Hazel, B., Christiansen, J., Gram-Nielsen, S., Jeppesen,
C.B., Andersen, K.V., Halkier, T., Okkels, S., and Schambye, H.T. (2003).
Glycosylation of an N-terminal extension prolongs the half-life and increases
the in vivo activity of follicle stimulating hormone. J. Clin. Endocrinol. Metab.
88, 3227–3235.
Petitou, M., and van Boeckel, C.A.A. (2004). A synthetic antithrombin III bind-
ing pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed.
Engl. 43, 3118–3133.
Phalipon, A., Costachel, C., Grandjean, C., Thuizat, A., Guerreiro, C., Tanguy,
M., Nato, F., Vulliez-Le Normand, B., Be´lot, F., Wright, K., et al. (2006). Char-
acterization of functional oligosaccharide mimics of the Shigella flexneri sero-
type 2a O-antigen: implications for the development of a chemically defined
glycoconjugate vaccine. J. Immunol. 176, 1686–1694.
Phalipon, A., Tanguy, M., Grandjean, C., Guerreiro, C., Be´lot, F., Cohen, D.,
Sansonetti, P.J., and Mulard, L.A. (2009). A synthetic carbohydrate-protein
conjugate vaccine candidate against Shigella flexneri 2a infection.
J. Immunol. 182, 2241–2247.
Platt, F.M., Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H.,
Proia, R.L., Winchester, B., Dwek, R.A., and Butters, T.D. (1997). Prevention
of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
Science 276, 428–431.
Platt, E.J., Gomes, M.M., and Kabat, D. (2012). Kinetic mechanism for HIV-1
neutralization by antibody 2G12 entails reversible glycan binding that slows
cell entry. Proc. Natl. Acad. Sci. USA 109, 7829–7834.
Pozsgay, V. (2008). Recent developments in synthetic oligosaccharide-based
bacterial vaccines. Curr. Top. Med. Chem. 8, 126–140.ights reserved
Chemistry & Biology
ReviewPratt, M.R., and Bertozzi, C.R. (2005). Synthetic glycopeptides and glycopro-
teins as tools for biology. Chem. Soc. Rev. 34, 58–68.
Pukin, A.V., Branderhorst, H.M., Sisu, C., Weijers, C.A.G.M., Gilbert, M.,
Liskamp, R.M.J., Visser, G.M., Zuilhof, H., and Pieters, R.J. (2007). Strong
inhibition of cholera toxin by multivalent GM1 derivatives. ChemBioChem 8,
1500–1503.
Rabuka, D., Forstner, M.B., Groves, J.T., and Bertozzi, C.R. (2008). Noncova-
lent cell surface engineering: incorporation of bioactive synthetic glycopoly-
mers into cellular membranes. J. Am. Chem. Soc. 130, 5947–5953.
Rademacher, T.W., Parekh, R.B., and Dwek, R.A. (1988). Glycobiology. Annu.
Rev. Biochem. 57, 785–838.
Raju, T.S. (2008). Terminal sugars of Fc glycans influence antibody effector
functions of IgGs. Curr. Opin. Immunol. 20, 471–478.
Rathore, A.S., andWinkle, H. (2009). Quality by design for biopharmaceuticals.
Nat. Biotechnol. 27, 26–34.
Rawat, M., Gama, C.I., Matson, J.B., and Hsieh-Wilson, L.C. (2008). Neuroac-
tive chondroitin sulfate glycomimetics. J. Am. Chem. Soc. 130, 2959–2961.
Reivich, M., Kuhl, D., Wolf, A., Greenberg, J., Phelps, M., Ido, T., Casella, V.,
Fowler, J., Hoffman, E., Alavi, A., et al. (1979). The [18F]fluorodeoxyglucose
method for the measurement of local cerebral glucose utilization in man.
Circ. Res. 44, 127–137.
Rele, S.M., Cui, W., Wang, L., Hou, S., Barr-Zarse, G., Tatton, D., Gnanou, Y.,
Esko, J.D., and Chaikof, E.L. (2005). Dendrimer-like PEO glycopolymers
exhibit anti-inflammatory properties. J. Am. Chem. Soc. 127, 10132–10133.
Renaudet, O., and Dumy, P. (2003). Chemoselectively template-assembled
glycoconjugates as mimics for multivalent presentation of carbohydrates.
Org. Lett. 5, 243–246.
Rendle, P.M., Seger, A., Rodrigues, J., Oldham, N.J., Bott, R.R., Jones, J.B.,
Cowan, M.M., and Davis, B.G. (2004). Glycodendriproteins: a synthetic glyco-
protein mimic enzyme with branched sugar-display potently inhibits bacterial
aggregation. J. Am. Chem. Soc. 126, 4750–4751.
Rhee, J.-K., Baksh, M., Nycholat, C., Paulson, J.C., Kitagishi, H., and Finn,
M.G. (2012). Glycan-targeted virus-like nanoparticles for photodynamic ther-
apy. Biomacromolecules 13, 2333–2338.
Ribeiro-Viana, R., Sa´nchez-Navarro, M., Luczkowiak, J., Koeppe, J.R., Del-
gado, R., Rojo, J., and Davis, B.G. (2012). Virus-like glycodendrinanoparticles
displaying quasi-equivalent nested polyvalency upon glycoprotein platforms
potently block viral infection. Nat Commun 3, 1303.
Rich, J.R., and Withers, S.G. (2009). Emerging methods for the production of
homogeneous human glycoproteins. Nat. Chem. Biol. 5, 206–215.
Rillahan, C.D., Schwartz, E., McBride, R., Fokin, V.V., and Paulson, J.C. (2012).
Click and pick: identification of sialoside analogues for siglec-based cell tar-
geting. Angew. Chem. Int. Ed. Engl. 51, 11014–11018.
Sackstein, R. (2012). Glycoengineering of HCELL, the human bone marrow
homing receptor: sweetly programming cell migration. Ann. Biomed. Eng.
40, 766–776.
Sackstein, R., Merzaban, J.S., Cain, D.W., Dagia, N.M., Spencer, J.A., Lin,
C.P., and Wohlgemuth, R. (2008). Ex vivo glycan engineering of CD44 pro-
grams human multipotent mesenchymal stromal cell trafficking to bone. Nat.
Med. 14, 181–187.
Sakamoto, I., Tezuka, K., Fukae, K., Ishii, K., Taduru, K., Maeda, M., Ouchi, M.,
Yoshida, K., Nambu, Y., Igarashi, J., et al. (2012). Chemical synthesis of homo-
geneous human glycosyl-interferon-b that exhibits potent antitumor activity
in vivo. J. Am. Chem. Soc. 134, 5428–5431.
Sampathkumar, S.-G., Li, A.V., Jones, M.B., Sun, Z., and Yarema, K.J. (2006).
Metabolic installation of thiols into sialic acid modulates adhesion and stem
cell biology. Nat. Chem. Biol. 2, 149–152.
Sarkar, D., Vemula, P.K., Teo, G.S.L., Spelke, D., Karnik, R.,Wee, Y., and Karp,
J.M. (2008). Chemical engineering of mesenchymal stem cells to induce a cell
rolling response. Bioconjug. Chem. 19, 2105–2109.
Sarkar, D., Vemula, P.K., Zhao, W., Gupta, A., Karnik, R., and Karp, J.M.
(2010). Engineered mesenchymal stem cells with self-assembled vesicles for
systemic cell targeting. Biomaterials 31, 5266–5274.Chemistry & BiolSarkar, D., Spencer, J.A., Phillips, J.A., Zhao, W., Schafer, S., Spelke, D.P.,
Mortensen, L.J., Ruiz, J.P., Vemula, P.K., Sridharan, R., et al. (2011). Engi-
neered cell homing. Blood 118, e184–e191.
Sasisekharan, R., Raman, R., and Prabhakar, V. (2006). Glycomics approach
to structure-function relationships of glycosaminoglycans. Annu. Rev. Bio-
med. Eng. 8, 181–231.
Sato, M., Furuike, T., Sadamoto, R., Fujitani, N., Nakahara, T., Niikura, K.,
Monde, K., Kondo, H., and Nishimura, S.-I. (2004). Glycoinsulins: dendritic
sialyloligosaccharide-displaying insulins showing a prolonged blood-sugar-
lowering activity. J. Am. Chem. Soc. 126, 14013–14022.
Satoh, M., Iida, S., and Shitara, K. (2006). Non-fucosylated therapeutic anti-
bodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6,
1161–1173.
Sattin, S., Daghetti, A., The´paut, M., Berzi, A., Sa´nchez-Navarro, M., Tabarani,
G., Rojo, J., Fieschi, F., Clerici, M., and Bernardi, A. (2010). Inhibition of DC-
SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent
presentation. ACS Chem. Biol. 5, 301–312.
Saxon, E., and Bertozzi, C.R. (2000). Cell surface engineering by a modified
Staudinger reaction. Science 287, 2007–2010.
Schatz, A., Bugle, E., and Waksman, S.A. (1944). Streptomycin, a Substance
Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative
Bacteria. Proc. Soc. Exp. Biol. Med. 55, 66–69.
Schiestl, M., Stangler, T., Torella, C., Cepeljnik, T., Toll, H., and Grau, R. (2011).
Acceptable changes in quality attributes of glycosylated biopharmaceuticals.
Nat. Biotechnol. 29, 310–312.
Schmidt, C., Stehling, P., Schnitzer, J., Reutter, W., and Horstkorte, R. (1998).
Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-
substituted neuraminic acid precursor. J. Biol. Chem. 273, 19146–19152.
Schofield, L., Hewitt, M.C., Evans, K., Siomos, M.-A., and Seeberger, P.H.
(2002). Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria.
Nature 418, 785–789.
Schultz, M.J., Swindall, A.F., and Bellis, S.L. (2012). Regulation of themetasta-
tic cell phenotype by sialylated glycans. Cancer Metastasis Rev. 31, 501–518.
Schwarz, F., Huang,W., Li, C., Schulz, B.L., Lizak, C., Palumbo, A., Numao, S.,
Neri, D., Aebi, M., and Wang, L.-X. (2010). A combined method for producing
homogeneous glycoproteins with eukaryotic N-glycosylation. Nat. Chem. Biol.
6, 264–266.
Seeberger, P.H., andWerz, D.B. (2007). Synthesis and medical applications of
oligosaccharides. Nature 446, 1046–1051.
Sell, S. (1990). Cancer-associated carbohydrates identified bymonoclonal an-
tibodies. Hum. Pathol. 21, 1003–1019.
Sethuraman, N., and Stadheim, T.A. (2006). Challenges in therapeutic glyco-
protein production. Curr. Opin. Biotechnol. 17, 341–346.
Shields, R.L., Lai, J., Keck, R., O’Connell, L.Y., Hong, K., Meng, Y.G., Weikert,
S.H.A., and Presta, L.G. (2002). Lack of fucose on human IgG1 N-linked oligo-
saccharide improves binding to human Fcgamma RIII and antibody-depen-
dent cellular toxicity. J. Biol. Chem. 277, 26733–26740.
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakur-
ada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003). The
absence of fucose but not the presence of galactose or bisecting N-acetylglu-
cosamine of human IgG1 complex-type oligosaccharides shows the critical
role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem.
278, 3466–3473.
Shriver, Z., Raman, R., Viswanathan, K., and Sasisekharan, R. (2009). Context-
specific target definition in influenza a virus hemagglutinin-glycan receptor
interactions. Chem. Biol. 16, 803–814.
Sinclair, A.M., and Elliott, S. (2005). Glycoengineering: the effect of glycosyla-
tion on the properties of therapeutic proteins. J. Pharm. Sci. 94, 1626–1635.
Singh, S.K., Stephani, J., Schaefer, M., Kalay, H., Garcı´a-Vallejo, J.J., den
Haan, J., Saeland, E., Sparwasser, T., and van Kooyk, Y. (2009). Targeting
glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances
MHC class I and II presentation. Mol. Immunol. 47, 164–174.ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 35
Chemistry & Biology
ReviewSisu, C., Baron, A.J., Branderhorst, H.M., Connell, S.D., Weijers, C.A.G.M., de
Vries, R., Hayes, E.D., Pukin, A.V., Gilbert, M., Pieters, R.J., et al. (2009). The
influence of ligand valency on aggregation mechanisms for inhibiting bacterial
toxins. ChemBioChem 10, 329–337.
Slawson, C., Copeland, R.J., and Hart, G.W. (2010). O-GlcNAc signaling: a
metabolic link between diabetes and cancer? Trends Biochem. Sci. 35,
547–555.
Sletten, E.M., and Bertozzi, C.R. (2009). Bioorthogonal chemistry: fishing for
selectivity in a sea of functionality. Angew. Chem. Int. Ed. Engl. 48, 6974–6998.
Slovin, S.F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova,
M., Bornmann, W.G., Fazzari, M., Dantis, L., et al. (1999). Carbohydrate vac-
cines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide
conjugate in man. Proc. Natl. Acad. Sci. USA 96, 5710–5715.
Smyth, S., and Heron, A. (2006). Diabetes and obesity: the twin epidemics.
Nat. Med. 12, 75–80.
Sola´, R.J., and Griebenow, K. (2009). Effects of glycosylation on the stability of
protein pharmaceuticals. J. Pharm. Sci. 98, 1223–1245.
Somerville, C. (2006). Cellulose synthesis in higher plants. Annu. Rev. Cell Dev.
Biol. 22, 53–78.
Spiro, R.G. (2002). Protein glycosylation: nature, distribution, enzymatic for-
mation, and disease implications of glycopeptide bonds. Glycobiology 12,
43R–56R.
Stephan, M.T., and Irvine, D.J. (2011). Enhancing cell therapies from the
outside in: Cell surface engineering using synthetic nanomaterials. Nano
Today 6, 309–325.
Stork, R., Zettlitz, K.A., Mu¨ller, D., Rether, M., Hanisch, F.-G., and Konter-
mann, R.E. (2008). N-glycosylation as novel strategy to improve pharmaco-
kinetic properties of bispecific single-chain diabodies. J. Biol. Chem. 283,
7804–7812.
Styslinger, T.J., Zhang, N., Bhatt, V.S., Pettit, N., Palmer, A.F., andWang, P.G.
(2012). Site-selective glycosylation of hemoglobin with variable molecular
weight oligosaccharides: potential alternative to PEGylation. J. Am. Chem.
Soc. 134, 7507–7515.
Tamborrini, M., Werz, D.B., Frey, J., Pluschke, G., and Seeberger, P.H. (2006).
Anti-carbohydrate antibodies for the detection of anthrax spores. Angew.
Chem. Int. Ed. Engl. 45, 6581–6582.
Tao, M.H., and Morrison, S.L. (1989). Studies of aglycosylated chimeric
mouse-human IgG. Role of carbohydrate in the structure and effector func-
tions mediated by the human IgG constant region. J. Immunol. 143, 2595–
2601.
Tarp, M.A., and Clausen, H. (2008). Mucin-type O-glycosylation and its poten-
tial use in drug and vaccine development. Biochim. Biophys. Acta 1780,
546–563.
Thunberg, L., Ba¨ckstro¨m, G., and Lindahl, U. (1982). Further characterization
of the antithrombin-binding sequence in heparin. Carbohydr. Res. 100,
393–410.
Uman˜a, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J.E. (1999).
Engineered glycoforms of an antineuroblastoma IgG1 with optimized anti-
body-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176–180.
Valderrama-Rincon, J.D., Fisher, A.C., Merritt, J.H., Fan, Y.-Y., Reading, C.A.,
Chhiba, K., Heiss, C., Azadi, P., Aebi, M., and DeLisa, M.P. (2012). An engi-
neered eukaryotic protein glycosylation pathway in Escherichia coli. Nat.
Chem. Biol. 8, 434–436.
Van Epps, H.L. (2005). How Heidelberger and Avery sweetened immunology.
J. Exp. Med. 202, 1306–1306.
van Kasteren, S.I., Kramer, H.B., Jensen, H.H., Campbell, S.J., Kirkpatrick, J.,
Oldham, N.J., Anthony, D.C., and Davis, B.G. (2007). Expanding the diversity
of chemical protein modification allows post-translational mimicry. Nature
446, 1105–1109.
van Kasteren, S.I., Campbell, S.J., Serres, S., Anthony, D.C., Sibson, N.R., and
Davis, B.G. (2009). Glyconanoparticles allow pre-symptomatic in vivo imaging
of brain disease. Proc. Natl. Acad. Sci. USA 106, 18–23.36 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rvan Kooyk, Y., and Geijtenbeek, T.B.H. (2003). DC-SIGN: escape mechanism
for pathogens. Nat. Rev. Immunol. 3, 697–709.
van Kooyk, Y., and Rabinovich, G.A. (2008). Protein-glycan interactions in the
control of innate and adaptive immune responses. Nat. Immunol. 9, 593–601.
Varki, A. (1993). Biological roles of oligosaccharides: all of the theories are cor-
rect. Glycobiology 3, 97–130.
Va´zquez-Dorbatt, V., Lee, J., Lin, E.-W., and Maynard, H.D. (2012). Synthesis
of glycopolymers by controlled radical polymerization techniques and their ap-
plications. ChemBioChem 13, 2478–2487.
Verez-Bencomo, V., Ferna´ndez-Santana, V., Hardy, E., Toledo, M.E., Rodrı´-
guez, M.C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo,
M., et al. (2004). A synthetic conjugate polysaccharide vaccine against
Haemophilus influenzae type b. Science 305, 522–525.
von Itzstein, M., Wu, W.-Y., Kok, G.B., Pegg, M.S., Dyason, J.C., Jin, B., Van
Phan, T., Smythe, M.L., White, H.F., Oliver, S.W., et al. (1993). Rational design
of potent sialidase-based inhibitors of influenza virus replication. Nature 363,
418–423.
Walker, L.M., Phogat, S.K., Chan-Hui, P.-Y.,Wagner, D., Phung, P., Goss, J.L.,
Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al.; Protocol G Principal In-
vestigators. (2009). Broad and potent neutralizing antibodies from an African
donor reveal a new HIV-1 vaccine target. Science 326, 285–289.
Wang, L.-X. (2006). Toward oligosaccharide- and glycopeptide-based HIV
vaccines. Curr. Opin. Drug Discov. Devel. 9, 194–206.
Wang, L.-X., and Lomino, J.V. (2012). Emerging technologies for making
glycan-defined glycoproteins. ACS Chem. Biol. 7, 110–122.
Wang, L.-X., Tang, M., Suzuki, T., Kitajima, K., Inoue, Y., Inoue, S., Fan, J.-Q.,
and Lee, Y.C. (1997). Combined Chemical and Enzymatic Synthesis of a
C-Glycopeptide and Its Inhibitory Activity toward Glycoamidases. J. Am.
Chem. Soc. 119, 11137–11146.
Wang, Q., Zhang, J., and Guo, Z. (2007). Efficient glycoengineering of GM3 on
melanoma cell and monoclonal antibody-mediated selective killing of the gly-
coengineered cancer cell. Bioorg. Med. Chem. 15, 7561–7567.
Wang, Q., Ekanayaka, S.A., Wu, J., Zhang, J., and Guo, Z. (2008a). Synthetic
and immunological studies of 50-N-phenylacetyl sTn to develop carbohydrate-
based cancer vaccines and to explore the impacts of linkage between carbo-
hydrate antigens and carrier proteins. Bioconjug. Chem. 19, 2060–2067.
Wang, S.-K., Liang, P.-H., Astronomo, R.D., Hsu, T.-L., Hsieh, S.-L., Burton,
D.R., andWong, C.-H. (2008b). Targeting the carbohydrates on HIV-1: Interac-
tion of oligomannose dendrons with human monoclonal antibody 2G12 and
DC-SIGN. Proc. Natl. Acad. Sci. USA 105, 3690–3695.
Wang, L., Pulk, A., Wasserman, M.R., Feldman, M.B., Altman, R.B., Cate,
J.H.D., and Blanchard, S.C. (2012). Allosteric control of the ribosome by
small-molecule antibiotics. Nat. Struct. Mol. Biol. 19, 957–963.
Watkins, W.M. (2001). The ABO blood group system: historical background.
Transfus. Med. 11, 243–265.
Watkins, W.M., and Morgan, W.T. (1955). Inhibition by simple sugars of en-
zymes which decompose the blood-group substances. Nature 175, 676–677.
Watt, G.M., Lund, J., Levens, M., Kolli, V.S.K., Jefferis, R., and Boons, G.-J.
(2003). Site-specific glycosylation of an aglycosylated human IgG1-Fc anti-
body protein generates neoglycoproteins with enhanced function. Chem.
Biol. 10, 807–814.
Weinbaum, S., Tarbell, J.M., and Damiano, E.R. (2007). The structure and
function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 9,
121–167.
Weı¨wer, M., Chen, C.-C., Kemp, M.M., and Linhardt, R.J. (2009). Synthesis
and Biological Evaluation of Non-Hydrolyzable 1,2,3-Triazole-Linked Sialic
Acid Derivatives as Neuraminidase Inhibitors. Eur. J. Org. Chem. 2009,
2611–2620.
Wennekes, T., van den Berg, R.J.B.H.N., Boot, R.G., van der Marel, G.A.,
Overkleeft, H.S., and Aerts, J.M.F.G. (2009). Glycosphingolipids—Nature,
Function, and Pharmacological Modulation. Angew. Chem. Int. Ed. 48,
8848–8869.ights reserved
Chemistry & Biology
ReviewWilkinson, B.L., Day, S., Chapman, R., Perrier, S., Apostolopoulos, V., and
Payne, R.J. (2012). Synthesis and immunological evaluation of self-assembling
and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Chemistry 18, 16540–16548.
Witte, K., Sears, P., Martin, R., and Wong, C.-H. (1997). Enzymatic glycopro-
tein synthesis: Preparation of ribonuclease glycoforms via enzymatic glyco-
peptide condensation and glycosylation. J. Am. Chem. Soc. 119, 2114–2118.
Xia, L., McDaniel, J.M., Yago, T., Doeden, A., andMcEver, R.P. (2004). Surface
fucosylation of human cord blood cells augments binding to P-selectin and E-
selectin and enhances engraftment in bone marrow. Blood 104, 3091–3096.
Xiao, J., Chen, R., Pawlicki, M.A., and Tolbert, T.J. (2009). Targeting a homo-
geneously glycosylated antibody Fc to bind cancer cells using a synthetic
receptor ligand. J. Am. Chem. Soc. 131, 13616–13618.
Xu, Y., Masuko, S., Takieddin, M., Xu, H., Liu, R., Jing, J., Mousa, S.A., Lin-
hardt, R.J., and Liu, J. (2011). Chemoenzymatic synthesis of homogeneous
ultralow molecular weight heparins. Science 334, 498–501.
Yarema, K.J., and Bertozzi, C.R. (2001). Characterizing glycosylation path-
ways. Genome Biol. 2, reviews0004.1–reviews0004.10.
Yarema, K.J., Mahal, L.K., Bruehl, R.E., Rodriguez, E.C., and Bertozzi, C.R.
(1998). Metabolic delivery of ketone groups to sialic acid residues. Application
To cell surface glycoform engineering. J. Biol. Chem. 273, 31168–31179.
Yuan, C.L. (1978). Synthesis of some cluster glycosides suitable for attach-
ment to proteins or solid matrices. Carbohydr. Res. 67, 509–514.
Yuan, Y., Chen, J., Wan, Q., Wilson, R.M., and Danishefsky, S.J. (2010).
Toward fully synthetic, homogeneous glycoproteins: advances in chemical
ligation. Biopolymers 94, 373–384.Chemistry & BiolYuzwa, S.A., Macauley, M.S., Heinonen, J.E., Shan, X., Dennis, R.J., He, Y.,
Whitworth, G.E., Stubbs, K.A., McEachern, E.J., Davies, G.J., and Vocadlo,
D.J. (2008). A potent mechanism-inspired O-GlcNAcase inhibitor that blocks
phosphorylation of tau in vivo. Nat. Chem. Biol. 4, 483–490.
Yuzwa, S.A., Shan, X., Macauley, M.S., Clark, T., Skorobogatko, Y., Vosseller,
K., and Vocadlo, D.J. (2012). Increasing O-GlcNAc slows neurodegeneration
and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393–399.
Zaia, J. (2008). Mass spectrometry and the emerging field of glycomics. Chem.
Biol. 15, 881–892.
Zhang, Q., Collins, J., Anastasaki, A., Wallis, R., Mitchell, D.A., Becer, C.R.,
and Haddleton, D.M. (2013). Sequence-controlled multi-block glycopolymers
to inhibit DC-SIGN-gp120 binding. Angew. Chem. Int. Ed. Engl. 52, 4435–
4439.
Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie-Wylie, A., Culm-
Merdek, K., Park, A., Pan, C., and Edmunds, T. (2008). Development of a
simple and rapid method for producing non-fucosylated oligomannose con-
taining antibodies with increased effector function. Biotechnol. Bioeng. 99,
652–665.
Zhu, X., and Schmidt, R.R. (2009). New principles for glycoside-bond forma-
tion. Angew. Chem. Int. Ed. Engl. 48, 1900–1934.
Zhu, J., Wan, Q., Lee, D., Yang, G., Spassova, M.K., Ouerfelli, O., Ragupathi,
G., Damani, P., Livingston, P.O., and Danishefsky, S.J. (2009). From synthesis
to biologics: preclinical data on a chemistry derived anticancer vaccine. J. Am.
Chem. Soc. 131, 9298–9303.ogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 37
